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Pancreatic ductal adenocarcinoma is the fourth most frequent cause for cancer-related 
deaths due to late diagnosis and limited response to chemotherapy. As one of the identified 
drug resistance mechanism, a distinct subpopulation of cancer stem cells (CSCs) has not only 
been shown to promote tumor progression and metastasis, but has also been implicated in 
tumor relapse based on intrinsic drug-resistance. Therefore, advancing our understanding on 
the mechanism of drug resistance in CSCs versus non-CSCs could lead to more effective 
therapeutic strategies. Since CSCs and non-CSCs share an identical genetic background, we 
studied the epigenetic regulation of CSCs as the defining regulatory machinery of CSCs. 
Using high-throughput miRNA expression analysis; we identified a panel of common 
miRNAs to be consistently underrepresented in Gemcitabine-treated tumors compared to 
untreated tumors. Subsequent gain-of-function and loss-of-function experiments 
demonstrated that the miR-17-92 cluster encoding six related microRNAs as the most 
strikingly suppressed miRNA family in chemoresistant CSCs is of crucial relevance for CSC 
function. Specifically, lentivirus-mediated over-expression of the miR cluster in CSCs 
significantly reduced their self-renewal, in vivo tumorigenicity, and resistance to Gemcitabine 
by down-regulation of multiple key genes belonging to the Nodal/TGF-β1 signaling cascade 
such as ALK4, TGFBR2, SMAD2, SMAD4 as well as direct inhibition of Nodal/TGF-β1-
responsive genes p21, p57 and TBX3. MiR-overexpression in CSCs also resulted in their 
enhanced proliferation, which eventually resulted in CSC exhaustion during serial 
transplantation via down-regulation of p21 and p57. Thus, our study identifies the miR-17-
92 cluster as an important family of miRNAs that play a crucial role in CSC biology 
including chemoresistance. Our findings indicate potential for developing modulators of this 
cluster to overcome drug resistance in pancreatic CSCs and eventually improve the miserable 
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 El adenocarcinoma pancreático es la cuarta causa principal de muerte relacionada con 
el cáncer debido a su diagnostico tardío y su mala respuesta  a la quimioterapia. Uno de los 
posibles mecanismos de quimioresistencia que ha sido descrito se basa en la existencia de un 
subconjunto de  células tumorales con propiedades troncales, denominadas células troncales de 
cáncer (CSC), las cuales impulsan el crecimiento del tumor de páncreas, metástasis y 
quimioresistencia. Por lo tanto, si podemos progresar en el conocimiento del mecanismo de 
resistencia a la quimioterapa en las células troncales de cáncer, probablemente nos ayudaría a 
desarrollar terapias más eficientes. Debido a que las células troncales de cáncer y las células 
cancerígenas comparten un perfil genético idéntico, hemos estudiado la regulación epigenética 
de las CSCs para definir el mecanismo de regulación. Utilizando el análisis de expresión de los 
genes de miRNA, hemos identificado un grupo de miRNAs comunes que de manera 
consistente se encontraban poco expresados en aquellos tumores que habían sido tratados con  
Gemcitabina comparándolo  con los tumores sin tratar. Los experimentos posteriores de 
ganancia y perdida de funcionalidad, demostraron que el miR-17-92 cluster codificaba seis 
microRNAs  que se encontraban suprimidos en las CSCs quimioresistentes, lo cual era de 
crucial relevancia en la funcionalidad de las CSCs. 
Por consiguiente, al sobrexpresar  el miR cluster mediante el uso de un lentivirus en las CSCs, 
observamos que se reducía de manera significativa la capacidad de auto-replicación, 
tumorigenicidad in vivo y se reducía la resistencia a la Gemcitabina  via inhibición de la 
expresión de genes clave que pertenecen a la vía de señalizaciónn de Nodal/ TGF-β1 como 
ALK4, TGFBR2, SMAD2, SMAD4, así como también otros genes que responden a la 
inhibición tales como p21, p57 y TBX3. La sobreexpresión de miR en las CSCs también 
resultó en un aumento de la proliferación, lo cual eventualmente resultó en una disminución 
de la capacidad de auto-replicació en pases seriados debido a la reducción de la expresión de 
los genes p21 y p57. En resumen, nuestro estudio identifica el miR-17-92 cluster como una 
familia de miRNAs muy importante que juega un rol crucial en la biología de las CSC 
incluida la quimioresistencia. Nuestros hallazgos muestran un fuerte potencial para el posible 
desarrollo de modulaodores  de este cluster para poder suprimir la resistencia de las CSCs, y 
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ABCG2 ATP-binding cassette sub-family G member 2 
ALDH-1 Aldehyde dehydrogenases family 1 
ALK-4 Activin Receptor-Like Kinase 4 
BSA  Bovine Serum Albumin 
bFGF  Basic fibroblast growth factor 
CK19  Cytokeratin 19 
hCNT  (human) Concentrative nucleoside transporter 
CSC  Cancer Stem Cell 
CSCs  Cancer Stem Cells 
CXCR4 Chemokine receptor type 4 
DAPI  4',6-diamidino-2-phenylindole 
DMEM/F12 Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12  
DNA  Deoxyribonucleic acid 
DNP  2,4-Dinitrophenol 
EDTA Ethylenediaminetetraacetic acid 
hENT  (human) Equilibrative nucleoside transporter 
EpCAM Epithelial cell adhesion molecule 
5-FU  5-Fluoracil 
FACS  Fluorescent-activated cell sorting 
FBS  Fetal bovine serum 
FFPE   Formalin-Fixed, Paraffin-Embedded 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GEM  Gemcitabine 
HPF  High power fields 
HRP  Horseradish peroxidase 
KRAS  V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
mRNA messenger ribonucleic acid 
HNU mice Athymic Nude-Foxn1nu 
NSG mice NOD scid gamma mice 
PDAC Pancreatic ductal adenocarcinoma 
PaCSCs Pancretic cancer stem cells 
PBS  Phosphate buffered saline 
PEN  Penicillin  
PVDF  Polyvinylidene difluoride 
RT-qPCR quantitive real time polymerase chain reaction 
RIPA  Radioimmunoprecipitation assay   
RNA  Ribonucleic acid 
RPMI  Roswell Park Memorial Institute medium 
SSEA-1 Stage-specific embryonic antigen-1 
STREP Streptomycin 
SOC  Standard of care 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SDF-1 Stromal cell-derived factor 1 
TBS  Tris-buffered saline 
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1. THE PANCREAS 
The pancreas is a gland organ located transversely across the posterior wall of the abdomen, at 
the back of the epigastric and left hypochondriac regions. In adult humans it length varies 
from 15 to 25 cm., and its weight from 70 to 150 gr. The name pancreas derived from Greek 
roots “pan” meaning “all” and “creas” meaning “flesh or meat”, and is based on the fact that 
this organ lacks bones and cartilage (Slack, 1995, Buchler, 2002). The entire organ can be 
divided into four different regions: head, neck, body and tail (Figure I1). The head of the 
pancreas is the largest part and lays on the right side of the abdomen where the stomach is 
attached to the first part of the small intestine (the duodenum). The neck is a slight 
constriction between the head and the body that extends to the left side of the abdomen next 
to the spleen while its left extremity gradually tapers to form the tail. There is a duct that runs 
the length of the pancreas, and several small branches from the glandular tissue join it. The 
end of this duct is connected to a similar duct that comes from the liver, which delivers bile to 
the duodenum.  
 
The pancreas is classified as a heterocrine gland because it contains both endocrine and 
exocrine glandular tissue. The exocrine tissue represent about 85% of the pancreas by weight 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	  	  	   	  
Figure I1. Representative illustration showing the different regions of the pancreas: head, neck 
body and tail. Adapted from Lippincott Williams and Wilkens Atlas of Anatomy, 2009. 
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and secrete digestive enzymes, water and NaHCO3 into the intestine, while endocrine tissue 
makes up the other 15% and secretes hormones into the blood stream, such as insulin 
(Pandol, 2010).  
 
1.1. The endocrine pancreas 
The endocrine pancreas is composed by cells within the pancreas that synthesize and secrete 
hormones. The endocrine portion of the pancreas takes the form of many small clusters of 
cells called islets of Langerhans or, more simply, islets. In standard histological sections of the 
pancreas, islets are seen as relatively pale-staining groups of cells embedded in a darker-
staining exocrine tissue (Frohman, 1969). Pancreatic islets house three major cell types, each 
of which produces a different endocrine product:  
 
• Alpha cells (A cells) secrete the hormone glucagon that elevates the amount of glucose 
in the blood by promoting gluconeogenesis and glycogenolysis in the liver binding 
glucagon receptor (Youngs, 1972) 
• Beta cells (B cells) are the most abundant of the islet cells and produce insulin that is 
necessary to remove excess glucose from the blood (Krahl, 1974). 
• Delta cells (D cells) secrete the hormone somatostatin which is also produced by a 
number of other endocrine cells in the body and via interaction with G protein-
coupled somatostatin receptor, inhibits the release of numerous secondary hormones 
in the gastrointestinal system and pituitary gland (Gahete et al.) 
• PP cells which secrete pancreatic polypeptide (PP) (Slack, 1995) 
• Epsilon cells represents <1% and produces gherlin, a potent stimulator of growth 
hormone secretion from the pituitary gland (Kojima et al., 1999).	  
 
Interestingly, the distribution of the several cell type is very specific: beta cells occupy the 
central portion of the islet and are surrounded by a "rind" of alpha and delta cells. Moreover, 
the islets are richly vascularized, allowing the rapid secretion of the hormones to the 
circulation (Figure I2). Although islets comprise only 1-2% of the mass of the pancreas, they 
receive about 10 to 15% of the pancreatic blood flow. Additionally, they are innervated by 
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parasympathetic and sympathetic neurons, and nervous signals clearly modulate secretion of 
insulin and glucagon. (Pandol, 2010).  
 
 
The most important disease of endocrine pancreas disease is the Diabetes mellitus 
characterized by high blood sugar levels due to disruption of insulin producing beta cells 
(Type I – insulin dependent) or due to a variety of different events where different organs no 
longer respond to the effects of insulin (Type II or non insulin dependent) (Slack, 1995).  
In addition to diabetes, the endocrine pancreas can also suffer transformation of 
neuroendocrine cells, resulting in pancreatic neuroendocrine tumours that can be either 
functional (produce hormones) or non-functional (produce no hormones). Most functional 
neuroendocrine tumours are benign. However, 90% of non-functional neuroendocrine 
tumours are cancerous. The frequency of these tumours is very low (1-2%) while 95% are 
adenocarcinomas, which arises from the exocrine pancreas (Kloppel and Heitz, 1988). 
 
1.2. The exocrine pancreas  
The exocrine part of the pancreas is composed by tubuloacinar glands organised like bunches 
of grapes and surround the islets of Langerhans; the main ducts, blood vessels and nerve fibers 
	  
	   	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure I2. Representative illustration of an islet of Langerhans within the exocrine mass 
representing different types of endocrine cells. Adapted from (Bardeesy and DePinho, 2002)       	  
INTRODUCTION	  	  
24	   	  	  
are surrounded by connective tissue. It is mainly composed of two different types of cells: 
acinar and ductal cells. Acinar cells are pyramidal epithelial cells that secrete the digestive 
enzymes of the pancreatic juice, such as proteases, amylases, lipases and nucleases into the 
acinus lumen, which are essential for transforming and processing food into nutrients that can 
be absorbed by the intestine. Ductal cells are cuboidal to pyramidal in shape and secrete 
bicarbonate and mucus into the enzyme mixture. This enzyme mixture is secreted into the 
ducts, which empty into the duodenum (Figure I3) (Pandol, 2010, Bardeesy and DePinho, 
2002, Slack, 1995).  
 
Apart from acinar and ductal cells, there are several resident cells in the exocrine pancreas 
including pancreatic stellate cells (PaSCs). They are present in the periacinar space and have 
long cytoplasmic processes that encircle the base of the acinus, but also in perivascular and 
periductal regions of the pancreas participate in chronic pancreatitis and pancreatic cancer. In 
these disorders, PaSCs participate in disease pathogenesis after transforming from a quiescent 
state into an “activated” state. In normal conditions are involved in tissue repair activities; 
however, under pathologic conditions, they are “activated” into a high proliferative 
myofibroblast-like cell that proliferates and secretes extracellular matrix proteins and growth 
factors, which can remodel the microenvironment (Omary et al., 2007). 
	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure I3. Representative illustration of the exocrine pancreas representing the different cell types 
(i.e. duct and acinar cells) in the acinus. Adapted from (Bardeesy and DePinho, 2002) 	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Pancreatitis is an inflammation of the pancreas where digestive enzymes are activated before 
they are secreted into the duodenum and begin attacking the pancreas. Acute pancreatitis is is 
a sudden attack causing inflammation and necrosis of the pancreas parenchyma that in 
general is a transient and mild disease. In contrast, chronic pancreatitis is persistent and 
uncontrolled inflammation that leads to permanent deterioration of the structure and function 
of the pancreas with extensive fibrosis. The most common cause is long-term alcohol abuse, 
but also smoking, genetic and autoimmunity (Buchler, 2002).  
The other major disease of the exocrine pancreas is the Pancreatic Ductal Adenocarcinoma 
(PDAC), which is believed to arise from the exocrine pancreas and is the most frequent type 
of pancreatic cancer (95% of cases). 
 
2. PANCREATIC DUCTAL ADENOCARCINOMA  
 
Pancreatic ductal adenocarcinoma (PDAC) is the deadliest solid cancer and currently the 
fourth most frequent cause of cancer-related deaths world-wide (Jemal et al., 2010). In 
contrast to the general trend of decreasing incidences for most cancers, the incidence and 
death rates for PDAC continue to increase (“Cancer Facts & Figs. 2011”, American Cancer 
Society, www.cancer.org). Similar trends are noted for Europe, where cancer-related deaths 
have declined for most other cancers, but have increased by 20% for PDAC (WHO European 
Health Report 2012, (Han and Von Hoff, 2013).  
Has been estimated that 10% of PDAC cases are associated with an inherited predisposition 
based on familial clustering (Schenk et al., 2001); around 20% of PDAC-prone familial cases 
shows several germline mutations, including those targeting the tumor suppressor genes 
INK4A, BRCA2, and LKB1, the DNA mismatch repair gene MLH1 (Jaffee et al., 2002). Due 
to the low penetrance of PDAC and the typical age of onset associated with the above 
germline mutations, these genetic lesions appear to impact malignant progression of precursor 
lesions rather than cancer initiation. Supporting this hypothesis, INK4A and BRCA2 
mutations are not detected in the earliest sporadic PDAC premalignant lesions but are only 
found in the later intermediate or advanced pancreatic intraepithelial neoplasm (PanIN) 
lesions (Wilentz et al., 1998); (Goggins et al., 2000). Moreover, several genetic syndromes 
have been associated with an increased risk of pancreatic cancer including familial atypical 
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multiple mole melanoma (p16/CDKN2A) (Lynch et al., 2002), hereditary non-polyposis 
colorectal syndrome (HNPCC) (Canto et al.) and familial pancreatitis (Lowenfels et al., 
1997).  
How these genetic conditions lead to PDAC remains not fully understood, but few known 
risk factors have been directly linked to development of PDAC. Long-standing chronic 
pancreatitis could promote tumourigenesis in part by promoting the local release of cytokines 
and reactive oxygen species (ROS) that induce cell proliferation, disrupt cell differentiation 
states, and select for oncogenic mutations (Hezel et al., 2006).  
Moreover, smoking has been identified as clear risk factors since has been demonstrated that 
smokers have around a 3 times higher risk of developing pancreatic cancer than no-smokers 
(Hassan et al., 2007). In addiction, diabetes and obesity appear to confer increased risk of 
PDAC (Everhart and Wright, 1995, Gapstur et al., 2000, Michaud et al., 2001, Berrington 
de Gonzalez et al., 2003), 
PDAC commonly arises in the head of the pancreas with infiltration into surrounding tissues 
including lymph node, spleen, and peritoneal cavity, preferentially metastasizing to the liver 
and lungs; even the smallest primary lesions commonly exhibit lympho-vascular invasion, 
suggesting a propensity for early distant spread. The disease is characterized by extensive 
desmoplasia with dense stroma due to a severe inflammation and activation of pancreatic 
stellate cells. The precursor lesions in PDAC can be divided into three groups based on the 
clinical and histopathologic analysis: mucinous cystic neoplasm that harbor an ovarian-type 
stroma (MCN), intraductal papillary mucinous neoplasm that grow into larger cystic 
structures (IPMN) and the most studied pancreatic intraepithelial neoplasia (PanIN) (Maitra 
et al., 2005). PanINs lesions can be identified and distinguishes based on morphological 
alterations relative to normal ducts that correlates with an increase in dysplastic growth 
(Hruban et al., 2001). Starting from normal ductal cells, the cells start to acquire a mucinous 
and columnar epithelium phenotypes that reflect PanIN-1A which then progress on to 
PanIN-1B lesions, and on to medium- and high-grade lesions: PanIN-2 and PanIN-3 lesions 
characterized by nuclear atypia and extensive architectural disorganization and are believed to 
be the final precursor to PDAC (Mihaljevic et al., 2010). The high-grade PanINs ultimately 
transform into PDAC with evidence of areas of invasion beyond the basement membrane. 
During PanIN-to-PDAC progression occurs several gene alterations: 1) telomere shortening 
that cause genetic instability (Mihaljevic et al., 2010) 2) KRAS mutations are the driving 
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activating mutations acquired during early events (Avila et al., 2012) and occur in greater than 
90% of PDAC patients 3) CDNK2A inactivation brings the P16 loss, which is a regulator of 
cell cycle during G1-S transition 4) P53 loss is not as frequent as the other mutations, around 
50-70%, but its loss represents a deregulation of the cell cycle due to the lack of checkpoints 
for DNA damage control or apoptosis 5) SMAD4 mutations, present in ~50% of cases, acts 
also as a tumour suppressor, and its loss or mutated form bring the deregulation of the TGF-
β signalling (Hidalgo and Von Hoff, 2012, Morris et al.) (Figure I4). 
 
 
Pancreatic cancer is more common in elderly people than younger people, and only 20% of 
patients present with potentially curable tumours, largely due to late diagnosis as a 
consequence of the lack of early symptoms and poor or ineffective diagnostics. Thus, the 1- 
and 5-year relative survival rates for PDAC are currently 25% and 6%, respectively also 
because the majority of PDAC patients show extensive metastases in secondary organs 
including the liver, lungs and bone marrow at the time of diagnosis. Moreover PDAC shows 
high resistance to both chemo- and radio-therapy that further limits the potential to 
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure I4. Representative illustration of the histopathological changes during PDAC progression 
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effectively treat these patients. Different types of treatment are available for patients with 
pancreatic cancer. Some treatments are standard (the currently used treatment), and some are 
being tested in clinical trials. Depending on the stage and location of the cancer as well as on 
your age, overall health and personal preferences, there are several treatments approaches. The 
first approach is surgical, aimed to eliminate the tumours using the Whipple procedure, very 
complex and invasive, in which the head of the pancreas, the gallbladder, part of the stomach, 
part of the small intestine, and the bile duct are removed. Enough of the pancreas is left to 
produce digestive juices and insulin. Although the procedure results in a five-year survival of 
20%, only ~20% of patients with localized disease can benefit (Philip et al., 2009). If the 
cancer has spread and cannot be removed, biliary and gastic bypass may be done as palliative 
surgery to relieve symptoms and improve quality of life. 
Chemotherapy may be used at any stage of pancreatic cancer. It is commonly used when 
the cancer is advanced and can’t be removed completely with surgery, however may also be 
used after the cancer has been removed with surgery to try to kill any cancer cells that have 
been left behind. This type of treatment is called adjuvant treatment that lowers the chance 
that the cancer will come back later, while neoadjuvant treatment is given before surgery to try 
to shrink the tumour. Advances in PDAC-specific therapies are summarized in Table I1 and 
detailed below.  
Gemcitabine: The introduction of the nucleoside-analogue Gemcitabine, in 1997, improved 
clinical response with respect to 5-Fluorouracil by increasing overall survival and reducing 
pain and suffering (Burris et al., 1997). Gemcitabine was subsequently adopted as the 
standard of care (SOC) and is still the primary chemotherapeutic choice in the clinic. 
Nevertheless, with a 5-year survival rate of 1–4% and a median survival period of 4-6 months 
(Ahlgren, 1996, Jemal et al., 2004, Philip et al., 2009, Rosenberg, 1997, Rothenberg et al., 
1996, Warshaw and Fernandez-del Castillo, 1992) the prognosis of patients with pancreatic 
cancer has remained poor.  
Erlotinib: It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor 
receptor (EGFR), which is highly expressed and occasionally mutated in various forms of 
cancer, including pancreatic cancer, which results in uncontrolled cell division. Unfortunately, 
erlotinib in combination with Gemcitabine has not resulted in a markedly improved median 
survival (Moore et al., 2007) compared to SOC.  
FOLFIRINOX: The use of FOLFIRINOX (combination therapy of oxaliplatin, Irinotecan, 
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fluorouracil, and leucovorin) in patients with metastatic pancreatic cancer has improved 
overall survival to 11.1 months as compared with Gemcitabine treatment alone (6.8 months). 
Compared to Gemcitabine, FOLFIRINOX was associated with a survival advantage but had 
increased toxicity; therefore, only a subpopulation of patients with good performance are 
likely to benefit from this combination therapy (Conroy et al., 2011).  
Abraxane: Abraxane is an albumin-bound paclitaxel particles that targets SPARC, which has 
been associated with poor prognosis, promoting metastasis and angiogenesis. A recent phase 
III clinical trial combining Gemcitabine with Abraxane (paclitaxel albumin-bound particles), 
showed prolonged survival with the combination of both treatments with 8.5 (Abraxane and 
SOC) vs 6.7 (SOC) (Han and Von Hoff, 2013).  
Although tremendous efforts have been invested in improving our therapeutic approaches for 
treating patients with pancreatic cancer, all patients inevitably succumb to the disease. 
Therefore, new approaches for targeting pancreatic cancer are still desperately needed to pave 
the way for the development of disease-free treatment regimens (Hermann et al., 2009, 





Table I1. Current treatments for PDAC cancer. Adapted from (Han and Von Hoff, 2013) 	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3. ROLE OF CANCER STEM CELLS 
 
Tumours are generally assessed clinically by histology and by expression of specific markers 
and in combination with gene expression analysis; this has led to the definition of distinct 
tumour subtypes. In addition to different tumour subtypes, cells within the tumour 
population frequently exhibit functional diversity termed tumour heterogeneity (Heppner and 
Miller, 1983), with some cells exhibiting differences in proliferation and differentiation 
capacity. The fundamental cellular mechanisms underlying this tumour heterogeneity are 
subject of intense research activities. Based on the clonal model, a population of mutant cells 
within the tumour possess a growth advantage and are selected for expand during 
tumourigenesis, resulting in a homogenous tumour mass (Nowell, 1976), on the other hand 
the cancer stem cell (CSC) model, postulates a hierarchical organization of cells within the 
tumour such that only a small subset of “stem-like” cells is responsible for sustaining 
tumourigenesis and establishing the cellular heterogeneity inherent in the primary tumour 
(Clarke et al., 2006) (Figure I5). It is important to note that the two models are not mutually 
exclusive, as CSCs themselves undergo clonal evolution, as shown for leukaemia stem cells 
	   	  
 
 
Figure I5. Sources of heterogeneity. Cancer Stem Cell Model: Tumours contain different 
subpopulations of tumourigenic (cancer stem cells) and non-tumourigenic cells organized in a 
hierarchy. The Clonal evolution model: genetic/epigenetic changes in cancer cells with growth 
advantages are selected to repopulate the tumour mass. Adapted from	  (Laks et al.). 
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(Barabe et al., 2007). 
In 1997, pioneering studies from John Dick's laboratory identified for the first time leukemia-
initiating stem cells (Bonnet and Dick, 1997) followed by landmark studies in breast cancer 
(Al-Hajj et al., 2003a) and then rapidly emerging investigations on cancer stem cells (CSC), 
in numerous other solid tumours including glioblastoma (Singh et al., 2004), colorectal 
(Ricci-Vitiani et al., 2007), liver (Ma et al., 2007), and pancreatic cancer (Li et al., 2007a, 
Hermann et al., 2007a). 
Specific features including self-renew capacity, exclusively tumourigenic in vivo, characterize 
CSCs, including the capacity of producing all the cancer cell lineages within a tumour 
(Hermann et al., 2007a, Li et al., 2007b). 
The most clinical relevance of CSCs is the intrinsic resistance to standard chemotherapies 
compared to the their more differentiated progeny (Maugeri-Sacca et al.). Specifically, during 
treatment, while more differentiated cells regularly respond to chemotherapy, CSCs evade the 
effect of the chemotherapy, and upon termination of treatment, can again give rise to more 
differentiated progenies, recapitulating the heterogeneity of the tumour  (Figure I6).  
 
The mechanisms underlying chemoresistance can be schematically subdivided: 
 
• Proficient DNA repair machinery that preserve of the genetic code from exogenous or 
endogenous injuries maintaining normal cellular function. DNA sensor and repair 
pathways act in concert with apoptotic signaling to favors cancer stem cell survival 
	   	  
	  	  	  	  	  	   	  
Figure I6. During treatment, chemotherapy is able to kill more differentiated cells, while 
cancer stem cells are not affected by chemotherapy recapitulating the tumour heterogeneity upon 
treatment cessation. 	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• ABC drug transporters actively extrude from cancer stem cells a variety of structurally 
and functionally unrelated drugs of natural origin 
• Cell quiescence ensures cancer stem cells do not exhaust their proliferative potential 
and allow an efficient DNA damage repair and reenter the cell cycle. Quiescent CSCs 
are mostly spared by chemotherapy-induced cytotoxicity (because affecting the more 
proliferative cells) and are therefore capable of reconstituting the original tumour. 
 
It is worth some efforts to develop chemotherapy enhancing agents aimed at eliminating 
CSCs must take safety issues into account to avoid, or at least minimize, the inhibition of 
crucial mechanisms for normal stem cells. 
 
3.1 Markers for the identification of pancreatic cancer stem cells 
 
The first evidence for the existence of CSCs in pancreatic cancer was provided by Li et al. (Li 
et al., 2007b), in which they identified a highly tumourigenic CD44+CD24+EpCAM+ 
subpopulation of cells using immunocompromised mice xenografted with primary human 
pancreatic adenocarcinomas. Only these cells were able to form tumours at low numbers and 
only these cells displayed typical stem cell features like self-renewal, activation of 
developmental signaling pathways, generation of differentiated progeny and the ability to 
recapitulate the phenotype of the parental tumour from which they were derived. 
Unfortunately, it should be noted that in this first study, CSCs were compared to their triple-
negative counterparts (CD44-CD24-EpCAM-). Since EpCAM identifies epithelial cells 
within the tumour, it is possible that their EpCAM negative cells represented non-epithelial 
inflammatory stromal and vascular cells, or cells of mouse origin. Apparently, the finding that 
tumourigenicity in pancreatic cancer is confined to CD24+ cells is in stark contrast to the 
original findings in breast cancer, where only CD24- cells were tumourigenic. In a second 
study, Hermann et al. (Hermann et al., 2007a) showed that CD133 in pancreatic cancer cell 
lines and primary pancreatic cancers also reproducibly discriminates for cells with capacity for 
self-renewal, sphere formation, and, most importantly, in vivo tumourigenicity capability 
during serial passaging in vivo. Not surprisingly, CD133+ cells show some overlap with the 
CD44+CD24+EpCAM+ subpopulation. More recently, additional markers have also been 
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associated with pancreatic CSC: ALDH-1 has been shown to label tumourigenic cells in 
pancreatic and breast cancer (Feldmann et al., 2007, Jimeno et al., 2009, Rasheed et al., 
2010), although more recent data suggest an abundant expression of ALDH-1 in normal 
pancreas tissue (Deng et al., 2010), which may compromise the specificity of ALDH-1 as a 
marker for pancreatic CSCs. Indeed, ALDH-1 can be used for tumours whose normal tissue 
expression of ALDH-1 is limited or restricted, such as breast, lung, ovarian or colorectal 
tumours, or for circulating CSCs.  (Table I2). Since cell surface markers merely enrich for 
CSC populations, and therefore their use is controversial, functional assays like sphere 
formation capacity in vitro, and tumourigenicity in vivo, are becoming even more important 
for the identification of CSC. 
 
 
3.2 Migrating pancreatic cancer stem cells and metastasis 
 
Metastasis is the major cause of death in pancreatic cancer patients and currently there is no 
effective treatment available for this deadly disease. Increasing evidences suggest that not all 
cells within a tumour possess migrating capability; only a small subset of cells is directed 
through lymphatic or blood vessels towards specific secondary sites to form metastases. In 
order to be able to establish secondary lesions, the migrating cells would require similar 
features to the cells initiating the primary tumour. For this reason CSC were proposed to 
represent the only cell population capable of spreading and giving rise to metastases. Indeed, 
 
 
Table I2. Cancer Stem cell markers for pancreatic cancer. Adapted from (Hermann et al.) 	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Hermann et al. for the first time identified two distinct subsets of CSC based on the 
expression of the chemokine receptor CXCR4 in pancreatic cancer (Hermann et al., 2007a). 
CXCR4 is a chemokine receptor responding to chemotactic gradients of its specific ligand 
SDF-1 that was originally found to be responsible for leukocyte and hematopoietic progenitor 
cell homing. Emerging evidence suggests that CXCR4 plays a pivotal role in the metastatic 
process of different tumour entities towards a gradient of SDF-1, which is highly expressed in 
secondary sites usually associated with metastasis (liver, bone marrow) (Teicher and Fricker). 
Hermann et al. identified a “stationary” population expressing CD133, but not CXCR4, 
which is responsible for the initiation and maintenance of the primary tumour, and a 
“migrating” and highly metastatic population characterized by co-expression of CD133 and 
CXCR4. Consequently, pharmacological inhibition of the CXCR4 receptor by AMD3100 
prevented the metastatic activity of purified CSC. CD133+CXCR4+ CSCs were also found in 
patients with lymph node metastasis (pN1+), demonstrating a close clinical correlation 
between migrating CSC and advanced disease (Figure I7).  
 
	   	   	  
	   	   	  
Figure I7. A subpopulation of migrating cancer stem cells, identified by 
CD133+CXCR4+ is responsible for metastasis. Detection of these circulating CSC could serve as 
prognostic and therapeutic biomarker. Adapted from (Lonardo et al., 2010) 	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CSC in primary tumours may acquire a migrating phenotype through epithelial-
mesenchymal-transition (EMT), a complex process that involves several kinases and 
transcription factor that allows the transformation in a mesenchymal phenotype associated 
with strong migration capacity. Recently, Wellner et al. showed in pancreatic and colon 
cancers that the EMT-activator ZEB1 represents an important promoter of metastasis by 
suppressing E-cadherin and at the same time the stem cell phenotype was maintained by 
suppression of miR-200 family members that usually target stem cell factors such as Sox2 and 
Klf4 (Wellner et al., 2009). Taken together, these results suggest that in pancreatic cancer the 
metastatic process is not random, but rather regulated by specific mechanisms related to the 
expression of adhesion molecules, chemokine receptors like (i.e. CXCR4) and their respective 
ligands in secondary organs. 
 
3.3 Targeting pancreatic cancer stem cells  
 
Conventional anticancer therapy is directed to rapidly proliferating and differentiated cells 
that represent the bulk tumour, while sparing the undifferentiated CSCs. Such strategies 
often have limited efficacy because of intrinsic or acquired drug resistance and/or resistance to 
ionizing radiation (Frank et al.). While the majority of the cells undergo apoptosis after 
treatment with gemcitabine, the CD133+ CSCs are able to block the cell cycle in order to 
have more time to repair the DNA damage; as soon the treatment is withdrawn, these cells 
proliferate again producing the relapse of the tumour (Hermann et al., 2007a, Jimeno et al., 
2009). It is very important to understand the mechanism of chemoresistance in order to find 
specific therapy in combination with standard chemotherapy. Mechanisms of therapy 
resistance include increased recognition and repair of DNA damaged (Al-Assar et al., 2011), 
altered cell cycle checkpoint control and quiescence (Dean et al., 2005), enhanced anti-
apoptotic mechanisms (Visvader and Lindeman, 2008), and reduced drug accumulation as a 
result of increased expression of ABC transporters that efflux drugs (Goodell et al., 1996). 
These findings provide a rationale for the development of therapeutic strategies directed at 
targeting relevant molecular pathways in CSCs, or trying to force CSCs into a more 
differentiated state. Therapeutic approach able to target both CSCs and cancer bulk 
populations might prove most effective for tumour eradication and prevent relapse. 
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Nevertheless it is important to recognize that the CSC phenotype can display interindividual 
variability in particular tumours and that CSC-directed therapies might have limitations with 
regard to targeting every CSC in all patients (Xia et al., 2012). Some examples of CSC-
specific therapeutic targets and therapies are described below.  
 
1) The Sonic Hedgehog (Shh) is a secreted protein that inhibits the transmembrane receptor 
Patched, which leads to an activation of the Smoothened receptor that activates the 
transcription of the Gli protein family target genes. Shh pathway plays a critical role in 
embryonic development of the pancreas (Ingham and McMahon, 2001, Ruiz i Altaba et al., 
2002), and more recently in the progression and maintenance of pancreatic cancer and CSCs 
(Bailey et al., 2009, Morton et al., 2007). Transgenic mice with overexpressing Shh in the 
pancreatic endoderm developed pancreatic intraepithelial neoplasia (PanIN) and the 
accumulation of genetic Kras mutations demonstrating that Shh is an early mediator of PC 
tumourigenesis. Additionally, inhibition of Hedgehog signaling pathway by Cyclopamine 
retarded PC cell growth and induced apoptosis in vitro and in vivo (Thayer et al., 2003).  
More recently, inhibition of Shh pathway in mouse model of pancreatic cancer has shown to 
reduce the stroma content leading to a better delivery of chemotherapy improving survival 
(Olive et al., 2009). Recently, has been shown that pancreatic CSCs possess an increase 
activation of the Shh signaling pathway (Dembinski and Krauss, 2010), suggesting that 
inhibition of the Shh pathway could improve the outcomes of patients by elimination of 
CSCs. In a more preclinical scenario, it was demonstrate that only a triple combination 
therapy of Shh inhibitor (cyclopamine), the mTOR inhibitor (rapamycin), and Gemcitabine 
was capable to target CSCs in primary human pancreatic cancer cells (i.e. CD133+ cells), as 
shown by abrogation of the tumourigenic potential of cells that were pre-treated ex vivo with 
the triple therapy (Mueller et al., 2009). Even though these preclinical studies looks 
promising in terms of antitumour effect, unfortunately, advanced PDAC patients in clinical 
trials showed no improvement in median survival when treated with inhibitors of hedgehog 
pathway. Different clinical trial designs are needed to better target PDAC cancer and stroma. 
(Hidalgo and Von Hoff, 2012). 
 
2) mTOR signalling: The mammalian Target Of Rapamycin (mTOR) is an evolutionarily 
conserved serine/threonine kinase, that exerts its functions through phosphorylation of two 
INTRODUCTION	  	  
	   37	  	  
major downstream targets, the ribosomal protein S6 kinases and the eukaryotic translation 
initiation factor 4E-binding protein 1 playing a pivotal roles in many cellular processes 
including cell growth, cell division, cell cycle progression, and cell metabolism	   (Inoki et al., 
2005). Recently, the mTOR pathway has been reported to be involved in maintaining 
pancreatic CSCs in particular in CD133+ population within PDAC tumours. However, 
inhibition of the mTOR pathway by rapamycin resulted in a significant decreased of CD133 
population, as also observed for Shh pathway, was not efficient to completely eliminate the 
CSC pool (Mueller et al., 2009). 
 
3) Notch pathway: The notch pathway plays a pivotal role in cell-cell communication, 
embryogenesis, cellular homeostasis, cellular differentiation, apoptosis, and stem cell renewal. 
Four Notch receptors (Notch1–4) and five Notch ligands (Delta-like 1, 3, 4 and Jagged-1, -2) 
have been discovered: when a Notch ligand binds to an adjacent Notch receptor, Notch will 
be cleaved by multiple enzymes including γ-secretase, leading to release of the active Notch 
fragment and activation of Notch target genes including Akt, VEGF, mTOR and NF-kB 
(Ranganathan et al., 2011). Thus, Notch inhibition has been described to have an anti-
proliferative effect or enhancement of apoptotic activity (Hassan et al., 2013). Fan et al. in 
glioblastoma indicated that inhibition of Notch pathway by use of an inhibitor of γ-secretase 
(GSI-18) was also capable of significantly reducing the CD133+ Notch+ cell population, 
leading to the depletion of medulloblastoma side population cells and tumourigenicity 
capacity in (Fan et al., 2006). These findings might be also applicable to pancreatic CSCs, as 
Notch 2 has also been implicated in pancreatic cancer progression (Mazur et al., 2010).  
Another study by Tuveson et al. demonstrated in a mouse model for pancreatic cancer, that 
the gamma secretase inhibitor MRK003 inhibited Notch signalling in advance PDA but was 
not efficient to prolong survival of the mice. Only the combination therapy of MRK003 and 
Gemcitabine was capable to extend the lifespan (Cook et al., 2012). 
 
4) Nodal/ActivinA pathway: Nodal and Activin are members of TGF-ß family and have been 
shown to play an important role in human embryonic stem cell maintenance through binding 
to Activin-like type I (Alk4 and Alk7) or II receptors (ActRIIA and ActRIIB) on the surface 
of the cells, which leads to the phosphorylation of Smad proteins including Smad2 and 
Smad3 and the formation of a complex with Smad4 that migrate to the nucleus and activate 
INTRODUCTION	  	  
38	   	  	  
gene expression including Nanog and Oct4 (Minchiotti, 2005). More recently has been 
shown that Nodal/Activin is strongly expressed in pancreatic CSCs and are essential for the 
self-renewal capacity and “stemness” of pancreatic CSCs (Lonardo et al., 2011). Moreover 
also pancreatic stellate cells, which are present in the tumour stroma and serve as a niche for 
CSCs, expressed Nodal/Activin (Lonardo et al., 2012). Using primary pancreatic cancer cells, 
the authors showed that the inhibition of Nodal/Activin pathway in CSCs using SB431542, a 
specific inhibitor of the Nodal/Activin receptor Alk4, recombinant Lefty, a specific 
endogenous Nodal inhibitor, or genetic knockdown of Nodal/Alk4 and Smad4 using shRNA 
technology, abrogated their self-renewal capacity and tumourigenicity, and reversed the 
resistance of CSCs to gemcitabine. Importantly, the Nodal/Activin pathway lacks activity in 
adult tissues (e.g. normal pancreas) making it a realistic and plausible therapeutic target in 
patients with pancreatic cancer.  
 
 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure I8. Conventional therapies eliminates the bulk of the tumour but does not affect 
CSCs, resulting in a tumour relapsed. CSC target therapies, will kill or differentiate the CSCs, 
resulting in a loss of tumour initiating cells that will conduce to a regression. Adapted from (Ebben 
et al., 2010).(Green nuclei=CSC, blue and red nuclei=tumour cell) 	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In conclusion, developing new therapeutic strategies that include targeting of CSC bear great 
potential, but, given the enourmous intertumoural heterogeneity these efforts should also 
consider personalized approaches where a panel of available drugs is tested for individual 
response (Figure I8).  
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4. MicroRNA 
 
MicroRNAs belong to a class of non-coding RNAs that play key roles in the regulation of 
gene expression at post-transcriptional level (Bartel, 2004). MicroRNAs are generally 
transcribed by RNA polymerase II as large primary transcripts (pri-microRNA) that are 
processed by a protein complex containing the RNase III enzyme Drosha and the double-
stranded-RNA-binding protein, Pasha (also known as DGCR8) to form an approximately 70 
nucleotide precursor microRNA (pre-microRNA) with a stem-loop structure (Lee et al., 
2002, Esquela-Kerscher and Slack, 2006) (Figure I9).  
 
This precursor is subsequently transported to the cytoplasm by the RAN GTP-dependent 
transporter exportin 5 (Kim, 2004) where it is processed by a second RNase III enzyme, 
DICER, to form a mature microRNA of approximately 22 nucleotides (Hutvagner et al., 
2001). The mature miRNA:miRNA* duplex is then incorporated into a ribonuclear particle to 
	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  
 
Figure I9. The miRNA biogenesis pathway in vertebrate cells. Adapted from (Esquela-
Kerscher and Slack, 2006) 	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form the RNA-induced silencing complex, RISC, which negatively regulates its target genes. 
miRNAs are able to recognize their target mRNAs by as little as 6-8 nucleotides (the seed 
region) at the 3' untranslated regions UTR end of mRNA. Based on the complementarity 
between the miRNA and the target mRNA, there are two ways of inhibition: if the 
complementarity is perfect, the products follow the RNA-mediated interference (RNAi) 
pathway in which mRNA transcripts are degraded by ribonucleases (Hannon, 2002), while 
there is no degradation if the complementary is imperfect affecting only the protein target, 
but not the mRNA expression (Pillai et al., 2005). Since most target sites on the mRNA have 
only partial base complementarity with their corresponding microRNA, individual 
microRNAs may target as many as 100 different mRNAs. Moreover, individual mRNAs may 
contain multiple binding sites for different microRNAs, resulting in a complex regulatory 
network. In the same way, a single miRNA might bind as many as 200 gene targets and that 
these targets can be diverse in their function; so, miRNAs potentially control the expression 
30% of all human protein-encoding genes.  
In humans, approximately one third of miRNAs are organized in clusters. A given cluster is a 
single transcriptional unit, suggesting a coordinated regulation of miRNAs in the cluster. In 
silico analysis revealed that more than half of the clusters contain two or more miRNAs of 
similar sequence (Lee and Dutta, 2009). Members of the same cluster are similar in sequence, 
but can exert different and opposing biological effects. However, it is worth noting that all the 
miRNAs from a single transcriptional cluster are not expressed at equal levels, suggesting that 
miRNAs are also regulated post-transcriptionally. 
 
4.1 MicroRNAs and Cancer 
 
MicroRNAs have been shown to be involved in a wide range of biological processes such as 
cell cycle control, apoptosis and several developmental, physiological and pathological 
processes including stem cell differentiation, haematopoiesis, hypoxia and aging. In addition, 
highly tissue-specific expression and distinct temporal expression patterns during 
embryogenesis suggest that microRNAs play a key role in the differentiation and maintenance 
of tissue identity. MicroRNA has been also associated with cancer where can function as 
oncogene or tumour suppressor depending on the specific tumour, cell population and 
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microenviroment composition (Calin et al., 2004). Recently has been showed that about 50% 
of human miRNAs are located in areas of the genome containing fragile sites, frequently 
associated with cancer. This indicates that miRNAs might have a crucial function in cancer 
progression. For example, mir-125b-1 is located in a fragile site on chromosome 11q24, 
which is deleted in a subset of patients with breast, lung, ovarian and cervical cancer (Calin et 
al., 2004). In some other cases there is an aberrant expression of miRNA that act as oncogene, 
actively contributing to cancer development. There are several mechanisms that lead to an 
aberrant expression of miRNAs: 
 
• Genomic abnormality such as deletion, amplification, translocation. The first example 
of tumour suppressors miRNA is provided by Calin et al. in which identified a 
genomic deletions within the 13q14 locus in more than 65% of B-cell chronic 
lymphocytic leukemia (CLL) cases, as well as in 50% of mantle cell lymphomas, 16–
40% of multiple myelomas and 60% of prostate cancers. They hypothesized that in 
that 30kb region must reside a tumour suppressor gene and they identified two 
clustered miRNA genes, mir-15a and mir-16-1 (Calin et al., 2002). Further studies 
showed that miR-15a and miR-16-1 negatively regulate BCL2, which is an anti-
apoptotic gene that is often over-expressed in many types of human cancers, including 
leukaemias and lymphomas (Cimmino et al., 2005). 
 
• Epigenetic factors can influence the expression of miRNA through hypermethylation 
of CpG islands located very close of several miRNAs (79). Treatment of cancer cells 
with HDAC (histone deacetylase) inhibitor or with 5-aza-2′-deoxycytidine can up-
regulate specific miRNA (Scott et al., 2006). One example is miR-124a that is 
hypermethylated is tumour-type specific manner in colorectal tumours, while no 
methylation was seen in neuroblastoma where its expression is very high (Lujambio et 
al., 2007). 
 
• Regulation of miRNA processing steps is important to determine miRNA expression 
level. Although miRNAs from a genomic cluster are expressed from a common pri-
miRNA, the levels of individual miRNAs in the cluster are not necessarily coordinated 
(Lu et al., 2007). Moreover, miRNAs often exhibit a discrepancy in expression of the 
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mature form compared with its precursor due to mutations or alterations in expression 
level of several protein involved in miRNA biogenesis (Lee et al., 2008, Obernosterer 
et al., 2006). The altered expression levels of Dicer or Drosha have been demonstrated 
in several cancers (Chiosea et al., 2007, Muralidhar et al., 2007) likely due to change 
in copy number of the gene. Specifically Dicer has been implicated in heterochromatin 
maintenance and centromeric silencing, reduced protein levels might directly result in 
genomic instability and lead to tumour formation (Fukagawa et al., 2004). Moreover, 
the Argonaute proteins, which are crucial components of the RISC complex that 
direct both short interfering (siRNA)- and miRNA-mediated gene regulation, have 
also been associated with various cancers (Carmell et al., 2002). 
The majorities of miRNAs are expressed in a tissue specific manner and are different among 
cancers from various tissue origins. There are also some miRNAs that appear to be frequently 
deregulated in many cancers, suggesting that these miRNAs regulate fundamental processes 
during tumourigenesis. One example is the miR-17-92 cluster, located at chr13q31.3 in 
humans and composed of six miRNAs (mir-17, -18a, -19a, -20a, -19b-1, and -92a-1). The 
miR-17-92 cluster has been identified as potential oncogene for the first time in B-cell 
lymphoma where forced expression of the miR-17-92 cluster in transgenic mice 
overexpressing c-Myc oncogene significantly accelerated the oncogenic process (He et al., 
2005). Specifically, c-Myc is able to bind the genomic region upstream of the miR-17-92 
cluster and activates its expression (O'Donnell et al., 2005) together with E2F1 forming a 
positive feedback loop because E2F1 is a direct target of miR-17 and -20a (Sylvestre et al., 
2007). During proliferation, c-Myc and E2Fs turn on the miR-17-92 cluster that on the 
other way represses E2Fs, thereby preventing the uncontrolled amplification of the positive 
feedback loop between E2Fs and c-Myc: cycling cells will have elevated steady state levels of 
miR-17–92 due to the periodic burst of E2F activity during S phase, while quiescent cells will 
have reduced miR-17–92 levels (Woods et al., 2007). Consistent with its oncogenic role, the 
miR-17-92 cluster has been found up-regulated in a variety of cancers including lymphomas 
(Rinaldi et al., 2007), lung cancers (Hayashita et al., 2005), and others (Volinia et al., 2006) 
through amplification of chr13q31 locus (Ota et al., 2004). Recent evidences show that the 
miR-17-92 cluster, paradoxically could act as a tumour suppressor in some circumstances. 
Loss of heterozygosity at 13q12-q13 is associated with multiple tumour progression and poor 
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prognosis, including breast cancer, squamous cell carcinoma of the larynx, retinoblastoma, 
hepatocellular carcinoma and nasopharyngeal carcinoma (Xiang and Wu, 2010). Since c-Myc 
and E2Fs induces expression of the miR-17-92 cluster during proliferation of cells, the same 
cluster, which is able to down-regulates E2Fs, may serve as a brake on excessive proliferation 
acting as tumour suppressor. The miR-17-5p exerts its role of tumour suppressor in breast 
cancer cells by repressing the expression of amplified in breast cancer 1 (AIB1). Over-
expression or down-regulation of the miR-17-5p could suppress or promote breast cancer cell 
proliferation, respectively (Hossain et al., 2006). Recently, has been shown that over-
expression of miR-17-92 reduce tumourigenicity and induce apoptosis in gastrointestinal 
stromal tumour (GIST) by down-regulation of KIT and ETV1 (Gits et al., 2013).  
 
4.1 MicroRNAs and Cancer Stem Cells  
 
Recent studies suggest that miRNAs are able to regulate not only self-renewal and 
differentiation, but also important signalling pathways involved in the regulation of CSCs 
(Bao et al., 2010). Breast cancer stem cells (BCSCs) are the best characterized system in solid 
tumours and can be identified using surface markers CD44+CD24−/lo (Al-Hajj et al., 2003b)  
or Aldefluor assays (Ginestier et al., 2007). One of the first studies of miRNA regulation of 
CSCs shows that let-7 was significantly reduced in BCSCs (Yu et al., 2007). Based on this 
study, has been demonstrated that let-7 regulated self-renewal and differentiation, 
mammosphere formation, tumour formation, and metastasis in non-obese diabetic 
(NOD)/severe combined immunodeficient mice (SCID) by targeting H-RAS and HMGA2. 
Subsequently, miR-30 and miR-200 family were also found to be one of the miRNAs 
markedly reduced in BCSCs and to negatively modulate the stemness of BCSCs, suggesting 
that multiple miRNAs may regulate CSC properties (Yu et al., 2010, Shimono et al., 2009). 
The miR-200 family is also important for the maintenance of pancreatic cancer stem cells 
(PaCSCs) because is able to repress the expression of stem cell transcription factors such as 
Sox2 and Klf4. Furthermore, the members of this family (miR-141, miR-200a, b, c and miR-
429) can suppress the transcriptional repressor ZEB1, important for EMT and metastasis 
(Wellner et al., 2009, Spaderna et al., 2008) linking CSCs, miRNA and EMT process. In 
fact ZEB1 is expressed at the invasive front of pancreatic cancer and highly correlates with the 
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expression of miR-200 family members. Moreover the knockdown of ZEB1 resulted in an 
epithelial transition in pancreatic cancer cell lines with mesenchymal phenotype (MiaPaCa2 
and Panc1) and affected CSCs features such as spheres formation in culture and 
chemoresistance. Another CSC-regulating miRNA in pancreatic cancer is the miR-34 that is 
directly regulated by p53 and has been identified as tumour suppressor miRNA (Tarasov et 
al., 2007, Chang et al., 2007). Interestingly, miR-34 regulates Notch pathway and Bcl-2 that 
are important for CSCs maintenance. Restoration of miR-34 reduce CSC population, 
inhibits sphere formation in vitro and tumour formation in vivo (Ji et al., 2009). These results 
suggest that miRNA can be responsible for important pathway involved in CSCs biology and 
metastasis.  
 
The increasing knowledge of miRNA biology can open to new approaches in cancer diagnosis 
and therapy. Large-scale miRNA expression profiling of tumours versus normal tissue are 
useful to classify cancers and to define miRNA markers that might predict favourable 
prognosis.  
The administration of synthetic anti-sense oligonucleotides that encode sequences that are 
complementary to mature oncogenic miRNAs — termed anti-miRNA oligonucleotides 
AMOs) — might inactivate miRNAs in tumours and slow their growth. Formulations 
including conjugation with cholesterol improve stability, efficiency and toxicity in pre-clinical 
settings. Conversely, techniques to overexpress miRNAs by lentiviral approach or liposomal 
miR-mimics that function as tumour suppressors can be used to treat specific tumour types. 
Efficient over-expression of miR-34a in prostate cancer stem cells was able to reduce 
tumourigenicity and metastasis in a pre-clinical setting (Liu et al., 2011). Additional studies 
to improve the efficiency of these methods are needed before miRNA treatments can move 























































































































	   49	  	  
Pancreatic cancer is one of the most aggressive types of cancer due to intrinsic 
chemoresistance and early metastasis. Recently it has been demonstrated that pancreatic 
cancer contains a subpopulation of CSCs expressing CD133 that is essential for maintenance 
of tumour progression, metastatic spread and for the relapse after standard chemotherapeutic 
treatment (Hermann et al., 2007b). However, the mechanisms that govern self-renewal and 
resistance to chemotherapy remain poorly understood. Recently, it has been demonstrated 
that Nodal/Activin signalling is one of the master regulators of self-renewal in pancreatic 
cancer stem cells (Lonardo et al., 2011). Others mechanisms relevant for CSCs biology 
include epigenetic regulation through miRNAs, which have already been implicated in the 
regulation of normal stem cells as well as CSCs in other cancers (Croce and Calin, 2005, 
Melton et al., 2010, Yu et al., 2007, Shimono et al., 2009). Therefore, advancing our 
understanding about miRNA regulation of drug resistance and self-renewal in pancreatic 
CSCs could lead to novel and more effective therapeutic strategies for patients with 
pancreatic ductal adenocarcinoma. 
 
In the present PhD thesis project, we are aiming to:  
 
1. Identify modulated miRNA using high-throughput expression analysis of primary 
human PDAC cells resistant to chemotherapy and enriched for CSCs; 
2. Validate miRNAs significantly downregulated in chemo-resistant CSCs; 
3. Define the biological effect of the miRNA identified using loss of function and gain of 
function approaches; 
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El cáncer de páncreas es uno de los tipos de cánceres mas agreviso debido a su característica 
quimioresistente y pronta metástasis.. Recientemente, ha sido demonstrado que el cáncer de 
páncreas contiene una subpoblación de CSCs que expresan CD133. Se ha demostrado que el 
marcador CD133 es esencial en el mantenimineto y progresión del tumor, asi como está 
implicado en metástasis y recurriencia después del tratamiento con quimioterapia estándard  
(Hermann et al., 2007b). Sin embargo, el mecanismo que conduce a la auto-replicación y 
resistencia a la quimioterapia todavía queda por entender. Recientemente, se ha demostrado 
que la via de señalización de Nodal/Activin es uno de las principales reguladores de la 
capacidad de auto-replicación en células troncales de cáncer (Lonardo et al., 2011). Otros 
mecanismos relevantes en la biología de las CSCs incluye la regulación epigenética a través de 
los miRNAs, los cuales han sido ya impliacos en la regulación de las células troncales normales 
, como también en otras CSCs de otros tipos de cánceres (Croce and Calin, 2005, Melton et 
al., 2010, Yu et al., 2007, Shimono et al., 2009). Por lo tanto, si progresamos en el 
entendimiento de la regulación de los miRNA  en la capacidad de auto-replicación y 
resistencia a quimioterapéuticos de las células troncales de cáncer, podría ayudar a conseguir 
nuevas estrategias para poder obtener terapias mas eficientes para estos pacientes con 
adenocarcinoma pancreático. 
 
En el presente proyecto de tesis doctoral, nuestro objetivo es: 
 
1. Identificar miRNA modulados usando análisis de expresión de alto contenido de 
células primarias de adenocarcinoma pancreático que son resistentes a  la 
quimioterapia y están enriquecidas en CSCs 
2. Validar los miRNAs que tienen una expresión significativamente menor en las CSCs 
que son quimioresistentes.  
3. Definir los efectos biológicos the los miRNA identificados usando la técnica de 
perdida y ganancia de funcionalidad; 
4. Identificar proteínas de los miRNA y validar su relevancia funcional en la biología de 
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1. MICE 
 
1.1 Study approval 
Mice were housed in the CNIO’s animal facility in accordance with institutional policies and 
federal guidelines. Animal treatments were approved by the Animal Experimental Ethics 
Committee of the Instituto de Salud Carlos III (Madrid, Spain). Human pancreatic tumours 
were obtained with written informed consent and after approval from the Ethics Committee 
of the Instituto de Salud Carlos III (Madrid, Spain).  
 
1.2 Xenograft 
PDAC xenografts, generated from patient-derived samples, were kindly obtained from 
Manuel Hidalgo’s group (CNIO, Spain). Primary tumours were minced into small fragments 
and then implanted subcutaneously, in duplicate, in 4 to 5 nude mice (NU-Foxn1nu; Charles 
River, Wilmington, MA, USA). Once tumours reached 1cm3, tumours were resected, minced 
and re-implanted in another set of female nude mice, following the protocol described in 
Rubio- Viqueira et al. (Rubio-Viqueira et al., 2006), and illustrated in Figure M&M1. 
    
Figure M&M1. Xenograft study scheme.  Tumour samples are implanted in F1 generation mice 
and then expanded in a cohort of nude mice. Adapted from Rubio-Viqueira et al., 2006. 	  
MATERIALS	  AND	  METHODS	  	  
60	   	   	  
1.3 Mice treatments 
Four to six week-old female nude mice were used as recipients for primary human xenograft 
transplantations and mCherry or GFP or ZsGreen sorted primary cells (see below). Upon 
reaching a volume of 200mm3, mice were assigned to the following treatment groups: 
Control, Abraxane (Celgene, NJ, USA) 50mg/kg twice weekly (i.v) during 15 days and 
Gemcitabine (Eli Lilly, IN, USA) 125mg/kg twice weekly (i.p.) during 40 days. 
 
1.4 In vivo tumourigenicity and metastasis assays 
Primary pancreatic cancer cells were sorted for mCherry or GFP depending on the Lenti-vector 
used as detailed below. For tumourigenicity assays, serial dilutions (104 103 102) of single-cells 
resuspended in MatrigelTM (BD Bioscience, Heidelberg, Germany) were subcutaneously injected 
into right and left flank of female nude mice. For serial in vivo transplantation the tumours were 
digested, sorted for GFP or ZsGreen and injected again in the same number of cells (104). For 
metastasis assays, 104 FACSorted mCherry positive, GFP or ZsGreen positive and negative cells, 
were resuspended in 1X PBS and intrasplenically injected into NSG mice as previously described 
(Sainz et al., 2012).  
 
2. CELL CULTURE 
 
2.1 Primary human cancer cells.  
Primary pancreatic cancer tumours were minced, mechanically (gentleMACS Dissociator; 
Miltenyi, Bergisch-Gladbach, Germany) and enzymatically digested with collagenase for 60 
min at 37°C followed by a centrifugation for 5 min at 1200 rpm (Mueller et al., 2009) (Stem 
Cell Technologies, Vancouver, BC). Cell pellets were resuspended and cultured in RPMI  
(Invitrogen, Alcobendas, Spain) supplemented with 10% FBS and 50 units/ml pen/strep.  
 
2.2 Sphere formation assay  
Spheres were generated by culturing ~2×104 pancreatic cancer cells in Ultra-Low attachment 
plates (Corning, USA) in suspension in serum-free DMEM/F12 supplemented with B27 
(1:50, Invitrogen, Alcobendas, Spain), 20 ng/ml bFGF and 50 units/ml pen/strep for a total 
of 7 days, allowing spheres to reach a size of >75µm. For serial passaging, 7-day-old spheres 
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were harvested using 40µm cell strainers, dissociated into single cells, and then re-cultured for 
7 additional days as previously described (Lonardo et al.). 
 
2.3 PKH26 assay. 
Human primary pancreatic cancer cells were labelled with PKH26, a red fluorescent cell 
membrane labelling dye (Sigma), according to manufacturer’s instructions. Every 7 days, cells 
were harvested and PKH26+ cells were determined using a FACS Canto II (BD) for a total 
of 4 weeks.  
 
2.4 Cell viability assay 
Cells were seeded in 96-well plates (Nalgen Nunc International, Penfield, NY) at a concentration 
of 103 cells per well in 100µL of complete medium. Cells were incubated for 24 hours after 
administration of compounds to allow an optimal attachment. Cytoxicity was measured using a 
sulforhodamine B (SRB)-based cytotoxicity assay as described previously (Limame et al., 2012). 
The protein absorbance of the viable cells at each concentration is expressed as the relative 
percentage of absorbance compared to the un-treated control well. Each experiment was carried 
out with three replicate wells for all conditions tested, and all the experiments were done in 
triplicate. 
 
2.5 Wound-healing assay 
Confluent cultures of primary cancer cells seeded in a 6-well plate were scratched using a 1ml 
pipette tip after overnight starvation. Cells were washed twice with PBS to remove cell debris and 
then incubated at 37°C with serum-free in media in the presence or absence of 300ng/ml 
recombinant human Nodal, 100ng/ml Activin, and 10ng/ml TGF-β1. Migration was evaluated 
24 h later by calculating the average size of the wound determined by measuring the size of the 
wound at three locations (n = 3 wounds per cell/treatment). 
 
2.6 Invasion and migration assays 
Invasion assays were performed using modified Boyden chambers filled with Matrigel™ 
(BioCoat®, BD Biosciences).  Human primary pancreatic cancer cells were added to the Matrigel™ 
coated inserts, and 750µl of serum-free medium with 300ng/ml recombinant human Nodal, 
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100ng/ml Activin, and 10ng/ml TGF-β1 was added to the lower chamber. The assay chambers 
were incubated for 22h at 37°C. Invaded cells were fixed in 4% PFA and stained with DAPI. 
DAPI-positive nuclei were quantified in 10 high-power fields (HPF). Invasion was then 
calculated as the number of cells in the lower chamber versus total seeded cells (in %).  
 
2.7 Plasmid construct and transfection  
pCAGA12-luc SMAD4 reporter is a synthetic Smad responsive luciferase reporter vector that  
was generated cloning 12xCAGA (consensus Smad binding element) into pGL3 basic plasmid 
(Promega) (Dennler et al., 1998, Savary et al., 2013). Human primary pancreatic cells were 
plated into 24-well plates and co-transfected with pCAGA12-luc SMAD4 reporter and control 
Renilla plasmid using Lipofectamine 2000 and after 48 hours Gaussian luciferase and Renilla 
luciferase were measured. Luciferase activity was plotted as a percentage of the mock transfection. 
 
2.8 3’ UTR luciferase reporter assays 
The GLuc-ALK4-3'-UTR clone and GLuc-Tbx3-3'-UTR clone (GeneCopoeia, Labomics, 
Nivells, Belgium) and a control 3’UTR-reporter construct were transfected in human embryonic 
kidney (HEK) 293T into 24-well plates and co-transfected using Lipofectamine 2000 
(Invitrogen) with 10 ng of a reporter plasmid containing the 3′ untranslated region (UTR) of 
ALK4 or Tbx3 inserted downstream of the Gaussian luciferase secreted reporter gene and the 
secreted alkaline phosphatase tracking gene and 50 nmol/L of miR-17-92 precursor or negative 
control. Gaussian luciferase and alkaline phosphatase activities were measured by luminescence in 
conditioned medium 48 hours after transfection using Dual‐Light® detection system 
(Genecopoeia). Luciferase activity was plotted as a percentage of the mock transfection. 
 
2.9 Antagomirs 
Knockdown of miR‐17-92 was achieved in vitro and in vivo by administering miR‐17, 18a, 19a, 
19b, 20a, 92 antagomir mix or scrambled control were chemically synthesized as 2!-O-
methyloligoribonucleotides by BioSpring (Frankfurt, Germany). The antagomirs are labeled with 
Cy3 and contain cholesterol that facilitate the entry into the cells and allow tracking them. 
 
2.10 Cell treatments 
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For chemoresistance studies, primary human cell lines were treated with Gemcitabine (100ng/ml) 
or Abraxane (10uM) for 7 days. Media with corresponding compound was replaced every 48h.  
 
3. FLOW CYTOMETRY 
 
3.1 Flow cytometry analysis  
For flow cytometry analysis, primary pancreatic cells, dissociated cells from spheres cultures or 
cells obtained from tumour digestions were stained using different combinations of antibodies. 
The following antibodies were used: anti-hCD133/1-APC or PE (Miltenyi Biotec); hEpCAM-
APC, hCD44-APC, hSSEA-1-APC, hCXCR4-APC, mCD45-APC, mCD146-FITC or 
appropriate isotype-matched control antibodies (all from BD, Heidelberg, Germany). DAPI was 
used for exclusion of dead cells. Cells were acquired with a FACS CANTO II instrument (BD, 
Heidelberg, Germany). Data were analysed with FlowJo 9.2 software (Tree Star, Ashland, OR).   
 
3.2 FACS sorting   
Primary pancreatic cells, dissociated cells from sphere cultures or cells obtained from tumour 
digestions were adjusted to a concentration of 106 cells/ml in Sorting buffer [1X PBS; 3% 
FBS (v/v); 3mM EDTA (v/v)]. DAPI was added to exclude dead cells at a concentration of 
2mg/ml. Cells were sorted with a FACS Influx instrument (BD, Heidelberg, Germany).  
 
3.3 Apoptosis assay  
Cancer cells and CSCs were plated at 3x105 cells/well in a 6-well multi-well and cultured in 
presence of gemcitabine (100ng/ml) for 7 days. Attached and floating cells were collected, 
resuspended and stained with Annexin V (550474; BD Bioscience) after incubation with Annexin 
V binding buffer (556454; BD Pharmingen). Cells were then incubated with DAPI.   
 
3.4 Cell cycle analysis   
Cells were trypsinized, washed in PBS, centrifuged, and pellets were fixed in 200µl of 70% 
ethanol and stored at -20°C until use. Cells were centrifuged and pellets resuspended in 200µl of 
PBS, and 10µg/mL of RNAse A was incubated for 1 hour at 37°C. Subsequently, cells were 
resuspended in propidium iodide solution (0.1% sodium citrate, 0.1% TritonX-100, and 
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50µg/mL propidium iodide). Cell-cycle analysis was carried out by flow cytometry (FACS-
CANTO). Data were analysed by FlowJO software. For the identification of G0 quiescent 
population, cells were fixed in 100% ethanol at -20°C overnight, washed with PBS twice and 
stained with Ki67 (BD, Heidelberg, Germany) for 30min at room temperature, followed by an 
additional wash with PBS. Cells were stained with DAPI to perform cell cycle analyses using a 
FACS CANTO II (BD) instrument.  
 
4. PROTEIN ANALYSIS 
 
4.1 Protein extraction and quantification 
Cells were harvested in RIPA buffer (Sigma) supplemented with a protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN). The cell lysate was centrifuged at 14,000 rpm and 
supernatant was collected. Protein lysates were quantified using a BCA Protein Assay 
Reagent kit (Pierce, Thermo Scientific). 
 
4.2 Western Blot  
Cells were harvested in RIPA buffer (Sigma) supplemented with a protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN). 50µg of protein was resolved by SDS-PAGE and 
transferred to PVDF membranes (Amersham Pharmacia, Piscataway, NJ). Membranes were 
sequentially blocked with 1X TBS containing 5% BSA (w/v), 1% chicken albumin (w/v) and 
0.1% Tween20 (v/v), incubated with a 1:1000 dilution of antibodies against p21 (2947), p27 
(3688), p57 (2557), Cyclin D1 (2926), pSMAD2 (3108) from Cell Signaling or GAPDH 
(ab8245), Tbx3 (ab58264), Nanog (ab14959) from Abcam overnight at 4ºC, washed 3 times 
with 1X PBS containing 0.05% Tween20 (v/v), incubated with horseradish peroxidase-
conjugated goat anti-rat or goat anti-mouse antibody (Sigma), and washed again to remove 
unbound antibody. Bound antibody complexes were detected with SuperSignal 
chemiluminescent substrate (Amersham, Barcelona, Spain). 
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5. RNA AND MICRORNA ANALYSIS 
 
5.1 RNA extraction from tissue or cells 
Total RNAs from human primary pancreatic cancer cells or livers of NSG mice were 
extracted with TRIzol (Life Technologies, Madrid, Spain) according to the manufacturer's 
instructions.  
 
5.2 RT-qPCR  
One microgram of total RNA was reverse-transcribed with SuperScript II reverse 
transcriptase (Life Technologies) using random hexamers. Quantitative real-time PCR was 
performed with an Applied Biosystems 7500 real-time thermocycler (Applied Biosystems, 
Alcobendas, Spain) using Fast SYBR Green (Qiagen, Barcelona, Spain) as per the 
manufacturer’s instructions. The list of utilized primers are shown in Table M&M1  
Table M&M1- RT-qPCR primers 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Gene Primer sense Primer antisense 
NANOG TGAACCTCAGCTACAAACAGGTG AACTGCATGCAGGACTGCAGAG 
KLF4 ACCCACACAGGTGAGAAACC ATGTGTAAGGCGAGGTGGTC 
SOX2 AGAACCCCAAGATGCACAAC CGGGGCCGGTATTTATAATC 
OCT3/4 CTTGCTGCAGAAGTGGGTGGAGGAA CTGCAGTGTGGGTTTCGGGCA 
NODAL AGCATGGTTTTGGAGGTGAC CCTGCGAGAGGTTGGAGTAG 
ACTIVIN AAAGCTTCATGTGGGCAAAG AATCTCGAAGTGCAGCGTCT 
TGFB1 CAACAATTCCTGGCGATACCT CGTTGATGTCCACTTGCAGT 
SMAD2 TCCCAGCAGGAATTGAGCCACA GTTCTGCTGGAGAGCCTGTGTCC 
SMAD4 CAGCACCACCCGCCTATGCC TGGAACACCAATACTCAGGAGCAGG 
ALK4 GGAGCGTCTTGTCTTTGGAG TGCAACAGGATCGACTTGAG 
TGFBRII CAACCACCAGGGCATCCA TCGTGGTCCCAGCACTCA 
TBX3 CGGGAAGGCGAATGTTTCCTCCA GGTCGGCCTTACCAGCCACC 
CD133 CAGAGTACAACGCCAAACCA AAATCACGATGAGGGTCAGC 
MCHERRY GCGCCTACAACGTCAACATC GCGTTCGTACTGTTCCACGA 
CDKN1A CCTGTCACTGTCTTGTACCCTTG AGAAGATCAGCCGGCGTTT 
CDKN1B TAATTGGGGCTCCGGCTAACT TTGCAGGTCGCTTCCTTATTC 
CDKN1C TCTGATCTCCGATTTCTTCGC TGCTGCTACATGAACGGTCC 
CYCLIN D1 CGTGGCCTCTAAGATGAAGGA CGGTGTAGATGCACAGCTTCT 
HCNT1 GGTGGCCTGCCTCCTGGATT AAGCAGCAAGAGCTAGACCCCTCT 
HCNT3 CTTTTCTGGAGTACACAGATGCT CGGCAGGACCTTAAATGCAAA 
HENT1 CTCTCAGCCCACCAATGAAAG CTCAACAGTCACGGCTGGAA 
HENT2 TCTCCAACTCTCAGCCCACCAA CCTGCGATGCTGGACTTGACCT 
ABCC1 GGAATACCAGCAACCCCGACTT TTTTGGTTTTGTTGAGAGGTGTC 
ABCG2 TCATGTTAGGATTGAAGCCAAAGGC TGTGAGATTGACCAACAGACCTGA 
B-ACTIN GCGAGCACAGAGCCTCGCCTT CATCATCCATGGTGAGCTGGCGG  
MATERIALS	  AND	  METHODS	  	  
66	   	   	  
5.3 miRNA microarray   
Total RNA concentrations extracted with Trizol were measured using a NanoDrop 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). The miRNA microarray 
experiments were performed using the Agilent Microarray Platform (Agilent Technology, Foster 
city, CA) G4471A-025987 miRNA array composed by 866 human miRNAs probes and the 
Human Gene Expression 4x44K v2 Microarray contain 34,127 Entrez Gene RNAs. 100 ng total 
RNA was hybridized with the miRNA array and for each miRNA, multiple probes were spotted 
on the array and the average intensity represent the expression value of the miRNA. In addition, 
multiple spots were included as negative controls. The arrays were scanned using an Agilent 
Technology G2565BA scanner and the scanned images were processed using the Feature 
Extraction software package version 9.5 (Agilent Technology). For the data processing we 
performed a global normalization via quantile normalization for each set of sample pair and 
subsequently a pairwise comparison via unpaired t-test and Benjamini Hochberg correction for 
false discovery rate.  
 
5.4 miRNA RT-qPCR  
For miRNA analysis, one microgram of total RNA was reverse-transcribed using the NCode 
VILO miRNA cDNA synthesis kit according to the manufacturer's instructions (Invitrogen). 
This step adds a polyadenylate tail to the miRNA population within the total RNA samples. 
The resulting cDNA was subjected to real-time PCR using SYBR Green ER qPCR Mix 
(Invitrogen). The Universal qPCR Primer was provided in the VILO kit and the forward 





6.1 Measuring γH2AX foci 
Cells were harvested and cytospins were made. Cells were fixed (2% formaldehyde), 
permeabilised (0.5% Triton/PBS) and labelled with anti-phsopho-γH2AX (Ser139) antibody 
(Millipore) overnight, 4°C. Cells were washed, labelled with goat anti-mouse-Alexa488 
secondary antibody (Invitrogen) and washed again. Slides were mounted in Vectashield 
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containing DAPI (Vector Laboratories). Images were taken with an Olympus FluoView 1000 
laser-scanning microscope (60x/1.4 PlanApo Oil lens). To quantify the number of γH2AX 




For histopathological analysis, FFPE blocks were serially sectioned (3 µm thick) and stained with 
haematoxylin and eosin (H&E). Additional serial sections were probed with antibodies against 
dsRed (Clontech, Saint-Germain, France), human cytokeratin 19α (abcam, Cambridge, UK), or 
in situ hybridization was performed using the Alu probe (Qbiogene, Bath, UK). Following 
incubation with primary antibodies, samples were incubated with HRP-conjugated secondary 
antibodies (DAKO, Barcelona, Spain) and positive cells were visualized using 3,3-
diaminobenzidine tetrahydrochloride plus (DAB+) as a chromogen. 
 
7. LENTIVIRUS   
 
To stably overexpress miR-17-92 cluster we used lentiviral particles carrying pre-miR17-92 
cluster in pcopGFP lentivector (System Biosciences, Mountain View, CA) and pPACK 
packaging mixture. To produce lentiviral particles carrying doxycicline-inducible miR 17-92, a 
custom lentiviral vector was constructed, with constitutively expressed mCherry and M2rtTA (a 
reverse doxycycline transactivator), and a custom-made promoter with the doxycycline operator 
and a minimal CMV promoter, under which the miR 17-92, amplified by PCR from pLVX-
eG2N-1792 (construct previously described), was cloned. Replication-incompetent lentiviral 
particles were then produced by calcium-phosphate transfection of HEK293T cells using the 
packaging plasmids pMD.2G (VSV-G) and pPAX2, as well as the doxycycline-induced miR 17-
92 as the shuttle vector. The medium was replaced for fresh DMEM complete 6h after 
transfection, and 48h afterwards the medium was collected, cleared by low-speed centrifugation, 
filtered through 0.45 µm pore-size PVDF filters, and stored in aliquots at -80ºC. To construct 
the lentiviral vectors carrying 5 different shRNAs targeting p21, a forward and a reverse 
oligonucleotide for each shRNA was designed, in order to reconstitute the shRNAs through an 
hybridization PCR and introduce restriction sites at the 5’ and 3’ of the shRNA for posterior 
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cloning. The oligonucleotides are shown in Table M&M2. The shRNAs were cloned in the 
lentiviral vector pLVX-shRNA2 from Clontech, under the control of the U6 promoter and with 
zsGreen as a transduction control. Replication-incompetent lentiviral particles were produced by 
calcium-phosphate transfection of HEK293T cells using the packaging plasmids pMD.2G 
(VSV-G) and pPAX2, as well as either one of the shRNA plasmids as shuttle vectors. The 
medium was replaced for fresh DMEM complete 6h after transfection, and 48h afterwards the 
medium was collected, cleared by low-speed centrifugation, filtered through 0.45 µm pore-size 
PVDF filters, and stored in aliquots at -80ºC. Subsequently the viruses are titered by flow 
cytometry analysis of mCherry or GFP expression in 293T cells infected with increasing 
dilutions of virus. For infection of primary PDAC cells, a multiplicity of infection of 10 
infectious units/ce was used and later sorted for mCherry, GFP or zsGreen. Tbx3 lentiviral 
vector and empty vector control were obtained from Origene. 
 
8. STATISTICAL ANALYSES 
 
Results for continuous variables are presented as means ± standard deviation unless stated 
otherwise and significance was determined using the Mann-Whitney test. All analyses were 
Table M&M2- shp21 sequences 
       	  	  	  	  	  	  
shRNA Sequence 
p21.1 FW gatccCCGGCTGATCTTCTCCAAGAGGAACTCGAGTTCCTCTTGGAGAAGATCAGCTTTTTGggtaccg  
p21.1 RV aattcggtaccCAAAAAGCTGATCTTCTCCAAGAGGAACTCGAGTTCCTCTTGGAGAAGATCAGCCGGg  
p21.2 FW gatccCCGGGCTGATCTTCTCCAAGAGGAACTCGAGTTCCTCTTGGAGAAGATCAGCTTTTTGggtaccg  
p21.2 RV aattcggtaccCAAAAAGCTGATCTTCTCCAAGAGGAACTCGAGTTCCTCTTGGAGAAGATCAGCCCGGg  
p21.3 FW gatccCCGGGACACCACTGGAGGGTGACTTCTCGAGAAGTCACCCTCCAGTGGTGTCTTTTTGggtaccg  
p21.3 RV aattcggtaccCAAAAAGACACCACTGGAGGGTGACTTCTCGAGAAGTCACCCTCCAGTGGTGTCCCGGg  
p21.4 FW gatccCCGGCCGCGACTGTGATGCGCTAATCTCGAGATTAGCGCATCACAGTCGCGGTTTTTGggtaccg  
p21.4 RV aattcggtaccCAAAAACCGCGACTGTGATGCGCTAATCTCGAGATTAGCGCATCACAGTCGCGGCCGGg  
p21.5 FW gatccCCGGGTCACTGTCTTGTACCCTTGTCTCGAGACAAGGGTACAAGACAGTGACTTTTTGggtaccg  
p21.5 RV aattcggtaccCAAAAAGTCACTGTCTTGTACCCTTGTCTCGAGACAAGGGTACAAGACAGTGACCCGGg  
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1. FUNCTIONAL ANALYSIS OF PANCREATIC CANCER STEM 
CELL  
It has shown that primary pancreatic CSCs can be enriched in vitro as anchorage-
independent spherical colonies termed spheres (Hermann et al., 2007b). These spheres are 
composed of a subset of cells with stem cell-like properties including the ability to form 
secondary spheres as well as more differentiated progenies. Furthermore, the enrichment and 
isolation of pancreatic CSCs using surrogate cell surface markers, such as the pentaspan 
transmembrane glycoprotein CD133, also known as Prominin-1, has been reported to 
enriched in CSCs from freshly isolated patient-derived samples (Hermann et al., 2007b).  
In the present study, we provide a more detailed characterization of spheres derived cells to 
functionally define the biological features of pancreatic CSCs. We used several human 
pancreatic adenocarcinoma xenografts or tumour-derived primary cell lines (A6L, 185, 354, 
215 and 253) that have been previously described (Jones and Wagers, 2008, Rubio-Viqueira 
et al., 2006). Importantly, all cells for in vitro experiments were freshly isolated from early 
passage xenografts and cultured as adherent cells (monolayer) or anchorage-independent 
spheres at low passages (Figure 1A). Cells were phenotyped by flow cytometry for the 
expression of CSCs markers; as previously reported (Lonardo et al.), spheres are enriched in 
CD133+ cells, as well as several other markers that have been associated with a CSC 
phenotype such as SDF-1 ligand CXCR4, and the differentiation marker stage-specific 
embryonic antigen-1 SSEA-1, as compared with adherent cells (Figure 1B). 
 
Figure 1. (A) Representative pictures of primary PDAC cells in monolayer and in spheres. 
(B) Flow cytometry of CD133+ CXCR4+ and CD133+ SSEA1+ cells is shown for primary 
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1.1. Cancer stem cell related genes 
 
In order to further characterize cancer stem cells in sphere culture, we determined the 
expression of pluripotency-associated genes (Nanog, Oct3/4, Stat3, Klf4, and Sox2) by real-
time PCR that has been extensively described as the “core transcription network” in the 
regulation of pluripotency in human and mouse Embrionic Stem Cells (ESC) and Induced 
Pluripotent Stem Cells (iPS) (Maherali et al., 2008, Takahashi and Yamanaka, 2006, 
Takahashi et al., 2007, Kim et al., 2008). Expression of pluripotency-associated genes was 
significantly higher in first generation sphere culture (d7) versus 70% confluent monolayer 
culture (Figure 2, left panel). Intriguingly, the expression levels observed for pancreatic 
spheres were comparable to those of human ESCs (data not shown).  
 
1.2. Cell cycle analysis 
 
To better characterize sphere-derived CSCs, we also analyzed the cell cycle profiles of sphere 
and adherent cultures, as previous work in other cancers suggest that cells with “stem-like” 
phenotypes bear distinct cell cycle profiles (Dembinski and Krauss, 2009, Chen et al., 2012, 
Li and Bhatia, 2011). We evaluated the expression of the cell cycle regulator genes p21, p27, 
p57, and Cyclin D1 at the mRNA level and we found significant over-expression of p21 and 
       
 
Figure 2. QPCR analysis of pluripotency-associated genes and cell cycle genes p21, p27, 
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p57 among several spheres derived cells, while Cyclin D1 is down regulated. p27 is 
significantly up-regulated only in A6L spheres derived cells (Figure 2, right panel).  
Expression of protein levels was evaluated for Nanog, p21, p27, p57 and cyclinD1 by western 
blotting, validating the results observed for gene expression. Protein levels of p27 show a 
consistent up regulation in spheres derived cells (Figure 3), suggesting different post-
translational modification or processing. 
 
We next analyzed the cell cycle profiles of sphere and adherent cultures, in order to 
functionally evaluate the change in gene and protein expression of the cell cycle proteins. 
Sphere-derived cells displayed a significant reduction of cells in S- and G2-M phase, which 
was accompanied by a notable enrichment for cells in G0 and G1 phases, respectively (Figure 
4). Consistent differences were observed for primary cultures derived from other primary 






Figure 3. Western blot analysis of Nanog and cell cycle genes p21, p27, p57 and Cyclin-
















78	   	  	  
 
To further validate the presence of a slow-cycling subpopulation in our primary pancreatic 
cancer cells, we assessed quiescence by using the lipophilic fluorescent dye PKH26, which is a 
label retaining dye that stains the cell membrane. Those cells that are more quiescent (slow 
cycling) will retain the label longer compare to those with a fast cycling. In fact, PKH26 
staining has recently been used to identify slow-cycling cancer stem cells in breast cancer 
(Pece et al., 2010) and melanoma (Roesch et al., 2010). The average doubling time of primary 
pancreatic cancer cells is ∼36 hr. Only 1-3% of the cells retained the maximum amount of 
label after 4 weeks suggesting that those cells had not divided (Figure 5). 
               
Figure 5. Representative pictures (upper panel) and flow cytometry analysis (lower panel) 
of PKH26 labeled cells after 1, 14 and 28 days in colture. 	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Flow cytometry analysis after 28 days in culture, reveals that PKH26 label-retaining cells 
expressed higher levels of surface CSC markers CD133, SSEA-1, and CXCR4 (Figure 6A). 
Moreover, when sorted, PKH26 label-retaining cells possess higher sphere formation capacity 
compared with negative cells (Figure 6B), suggesting that more quiescent cells possess CSC 





One of the clinical features of cancer stem cells is the ability to escape chemotherapy through 
several mechanisms and recapitulate the tumour heterogeneity, producing the relapse of the 
disease (Abdullah and Chow, 2013). We treated adherent cells and sphere derived cells with 
Gemcitabine (100ng/ml) during 48 hours and later we performed apoptosis analysis using 
AnnexinV assay. Interestingly we observed a massive increase of apoptotic cells in adherent cells, 







Figure 6. (A) Flow cytometry analysis for surface CSC markers CD133+, SSEA1+ and 
CXCR4+ in PKH26+ and PKH26- cells (B) Sphere formation capacity of PKH26+ and PKH26- 
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Figure 7. Flow cytometry analysis of apoptotic cells with AnnexinV and DAPI after   
treatment with Gemcitabine (100ng/ml) during 48 hours of adherent and sphere derived cells. 	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2. GEMCITABINE RESISTANT CELLS ARE ENRICHED FOR 
QUIESCENT CANCER STEM CELLS 
The aforementioned experiments show that spheres derived cells are enriched in 
cancer stem cells and that cancer stem cells possess a slow-cycling population that can be 
responsible of the resistant to chemotherapy (Li and Bhatia, 2011). In order to validate our 
findings in a different setup, we decided to analyze, both in vivo and in vitro, the biology and 
the phenotype of chemoresistant cells after treatment with gemcitabine.  
 
2.1. In vivo characterization of gemcitabine resistant cells 
 
In accordance with the hypothesis that chemotherapy preferentially targets non-CSCs, we 
treated several human primary tissue xenografts in immunocompromised mice. Mice with 
tumours measuring ≥200 mm3 (day 7) were then treated with Gemcitabine for 3 weeks 
(biweekly 125 mg/kg i.p.) (Figure 8A). Tumours were harvested, dissociated into single cells, 
and depleted for mouse hematopoietic cells and endothelial cells using MACS depletion for 
CD45 and CD146, respectively (Figure 8B) in order to have a more pure population for 
further analysis.  
      
Figure 8. (A) Human primary xenografts were treated with vehicle or 125 mg/kg/ 
biweekly Gemcitabine (treatment started at day 7 and ended at day 28 of x-axis). Tumor diameters 
were measured using calipers, and volume in mm3 was calculated. (B) Flow cytometry analysis of 
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Using the isolated and depleted cells from the tumours for flow cytometry analys, we observed 
a more prominent CSC subset in the Gemcitabine-resistant cell population that remained 
following treatment, defined by the increased expression of the surface markers CD133 and 
CXCR4 (Figure 9a). This apparent enrichment in CSCs was functionally validated at the 
level of sphere formation, where we observed markedly more sphere formation from 
Gemcitabine-treated tumour-derived cells compared to untreated controls (Figure 9B). 
 
 
To further characterize gemcitabine resistant cells, we performed gene expression analysis for 
stemness-related gene (Oct3/4, Sox2, Klf4, Nanog) and we observed that resistant cells 
possess “stem-like” phenotype due to overexpression of these gene compared with control 
cells (Figure 10A). Moreover, based on previous data showing the importance of 
Nodal/Activin signaling in the regulation of pancreatic cancer stem cells self renewal 
(Lonardo et al., 2011), we evaluate the expression of the genes involved in this pathway: Alk4, 
Nodal, Smad2, Smad4 in addiction to TgfbrII and Tgfb1. According to our hypothesis, we 
observed an increase in mRNA expression of the Nodal/Activin/TGF-β1 pathway members 
in Gemcitabine-treated tumours (Figure 10B). 
 
                                                                        
Figure 9. (A) Flow cytometry analysis for CD133 and CXCR4 after treatment with 
Gemcitabine. (B) Sphere formation capacity of Gemcitabine-resistant cells. Each bar represents 
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2.2. In vitro characterization of gemcitabine resistant cells 
 
To confirm these findings in vitro, we treated primary pancreatic cancer cell cultures 185 and 
A6L with Gemcitabine (100ng/ml) for 7 days, inducing >50% cell death. The CSC 
population, defined by CD133, CXCR4, and SSEA1 expression as assessed by flow 
cytometry, was increased in response to Gemcitabine (Figure 11A). Sphere formation 
capacity was also markedly increased by treatment with Gemcitabine in A6L cells and, albeit 
more modestly, in 185 cells (Figure 11B).  
                                                     
Figure 10. (A) Real-time PCR analysis for pluripotency associated genes (Oct3/4, Sox2, 
Klf4, Nanog) and (B) for genes involved in Nodal/Activin signaling (Alk4, Nodal, Smad2, Smad4, 











































Figure 11. (A) Flow cytometry of CD133+CXCR4+ and CD133+SSEA1+ cells is shown 
for primary PDAC A6L and 185 cells cultured as adherent cells or treated with Gemcitabine (B) 
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Subsequent cell cycle analyses revealed an increase of cells in G0 and G1 phases accompanied 
by a decrease of cells in S-phase (Figure 12A) and an increase in PKH26 label-retaining cells 
(Figure 12B), suggesting that Gemcitabine-resistant cells reside in a more quiescent state. 
This hypothesis was confirmed by quantitative real-time PCR (qPCR) analysis of cell cycle 
genes revealing higher levels of p21 and p57 and down-regulation of Cyclin-D1 in 
Gemcitabine-resistant cells (Figure 2C).  
 
Moreover increased expression of stemness-related genes (Oct3/4, Klf4, Sox2, Nanog) was 
observed in Gemcitabine-resistant cells, a pronounced EMT transcriptional phenotype, with 
increased expression of Snail and Zeb1 and down-regulation of E-cadherin, was also 
observed. We also noted differential expression of cellular transporters implicated in drug 
resistance (de Wolf et al., 2008, Sharom, 2008), such as up-regulation of the ABC-
transporters ABCC1 and ABCG2 and down-regulation of the Gemcitabine-specific 
transporters human concentrative nucleoside transporter (hCNT) and human equilibrative 
nucleoside transporter (hENT), both of which are necessary for Gemcitabine uptake and their 
expression levels are predictors of Gemcitabine response (Figure 13A) (Santini et al., 2010). 
We also observed an increase in mRNA expression of the Nodal/TGF-β1 pathway members 
ALK4, TGFBRII, SMAD2, SMAD4, and TBX3 (Figure 13B). Taken together, these data 
 
 
Figure 12. (A) Cell cycle analysis using ki67 and Dapi (B) Percentage of PKH26+ cells 
before and after gemcitabine treatment in A6L, 185 and 354 PDAC tumors. (C) QPCR analysis 
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demonstrate that culturing PDAC cells in the presence of Gemcitabine results in the 










Figure 13. (A) QPCR analysis of pluripotency-associated genes (Oct4, Sox2, Klf4 and 
Nanog), EMT genes (Snail, ZEB2 and E-cadherin), ABC transporters (ABCC1 and ABCG2) 
and Gemcitabine transporters (hENT1, hENT2, hCNT1 and hCNT3). Data are normalized for 
ß-Actin expression. (B) QPCR analysis of TGFBR2, ALK4, SMAD2, SMAD4 and TBX3 in 
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3. THE MIR-17-92 CLUSTER IS DOWNREGULATE IN CANCER 
STEM CELLS 
In order to identify miRNAs involved in the epigenetic regulation of self-renewal 
capacity and drug resistance of CSCs we compared miRNA expression profiles of 1) sphere-
derived cells with adherent cells and 2) primary human xenografts implanted in 
immunocompromised mice treated with either vehicle or Gemcitabine for 3 weeks and 
depleted for mouse hematopoietic and endothelial cells. We performed a global normalization 
via quintile normalization for each set of sample pairs and subsequently ran a pairwise 
comparison via unpaired t-test and Benjamini Hochberg correction for false discovery rate. 
Subsequently we identified several miRNAs presenting statistically significant differences 
between control and Gemcitabine-resistant cells (Figure 14A).  
      
 
Figure 14. (A) Microarray analysis, represented as heat-maps, of differentially regulated 
miRNA in PDAC cells treated with Gemcitabine (red and green boxes indicate up- and down-
regulation, respectively). (B) Venn diagram showing overlap between Gemcitabine-resistant and 
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As expected, we found commonly up-regulated miRNAs (miR-146a, miR-10b) along with 
commonly down-regulated miRNAs (miR-135a, miR-301, miR-7). Surprisingly, however, 
several members of the miR-17-92 family (miR-17, miR-18a, miR-19a, miR-19b, miR-20a*, 
miR-92a), which is commonly upregulated in bulk cancer tissue (Xiang and Wu, 2010), were 
also among the set of miRNAs downregulated in CSCs. To further validate our findings, we 
next compared the miRNA expression profile of Gemcitabine-resistant cells with the miRNA 
profiles obtained for sphere-derived cells versus adherent. Intriguingly, we again found 
consistent and statistically significant down-regulation of several members of miR-17-92 
family (miR-18a, miR-19a, miR-19b and miR-20a) together with miR-513a-5p and miR-
513b (Figure 14B). Importantly, we confirmed the down-regulation of several members of 
miR-17-92 family in an independent set of spheres derived cells and Gemcitabine-resistant 
cells by qPCR (Figure 15A) and reduction of miR-17-92 family members in PKH26-positive 
cells (Figure 15B). These data indicate that within highly proliferative bulk cancer cells, a 




           
  
Figure 15. (A) QPCR analysis of the member of miR 17-92 family in Gemcitabine 
resistant cells and spheres. (B) QPCR analysis of the member of miR 17-92 family in PKH26+ 
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4. MIR-17-92 INHIBITION USING ANTAGOMIRS PROMOTES 
CANCER STEM CELL PHENOTYPE 
In order to test the biological relevance of miR-17-92 in the context of pancreatic 
CSCs, we performed loss-of-function experiments by introducing an anti-sense inhibitor of 
miR-17-92 (termed miR-17-92 antagomir) conjugated with Cy3 into adherent pancreatic 
cancer cells that express high levels of this cluster and contain mostly differentiated cells, 
which are less tumourigenic compared to their less differentiated CSC counterparts (Lonardo 
et al., 2011). We transfected adherent cells derived from several primary pancreatic cancers 
that are more differentiated, with miR-17-92 antagomirs. We first assessed the expression of 
CSC surface markers CD133 by flow cytometry: we observed a significant increase in the 
expression of CD133 in several primary pancreatic cells (Figure 16A). Moreover, adherent 
cells trated with antagomir 17-92 show enhanced self renewal capacity as determined by 
sphere formation (Figure 16B) and overexpression of pluripotency-associated genes, ABC 
transporters and CD133 assessed by real time PCR (Figure 16C). 
                            
Figure 16. (A) Flow cytometry analysis for CD133 in cells treated with antagomirs. (B) 
Sphere numbers of cell treated with antagomir compared with control. (C) QPCR analysis of 
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Adherent cells possess a more proliferative and differentiated phenotype compared with the 
sphere-derived cells that are enriched in slow proliferating cells with CSC phenotype. Of 
note, adherent cells transfected with miR-17-92 antagomirs showed an increase in cells 
residing in G0 and G1 phase accompanied by a reduction of cells in S phase (Figure 17A). 
Protein analysis of antagomir treated cells, show a marked increase in p21 expression (Figure 
17B) that correlate with the change in cell cycle analysis since has been already described as 
one of the key player in haematopoietic (Cheng et al., 2000) and cancer stem cell quiescence 
(O'Brien et al., 2012). These alteration in cell cycle and p21 expression, translated into an 
increased chemoresistance after Gemcitabine treatment, similar to that of purified CSCs 
(Figure 17C). 
 
The most defining feature of CSCs is their ability to form tumours in vivo. We observed that 
adherent pancreatic cancer cells transfected with miR-17-92 antagomirs were markedly 
enhanced in their overall tumourigenicity (A6L: 4.2-fold [95% CI: 3.5-5.0] increase in CSC 
frequency; 185: 19.5-fold [16.2-23.4]), which did not only translate into higher tumour take 
rates, but also resulted in larger tumours compared to cells transfected with control 





Figure 17. (A) Cell cycle analysis using ki67 and Dapi (B) Western blot analysis of cell cycle 
gene p21 in adherent cells treated with AntagomiR-17-92. (C) Chemoresistance by Annexin 
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Taken together, these loss-of-function experiments in differentiated pancreatic cancer cells 
support the hypothesis that the miR-17-92 cluster negatively controls the tumourigenic 



















                                       
Figure 18. In vivo tumorigenicity of A6L and 185 treated with Antagomir-17-92. 
.  	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5. OVEREXPRESSION OF MIR-17-92 REVERSES CANCER STEM 
CELL PHENOTYPE 
Building upon our loss-of-function experiments using antagomirs, we next 
overexpressed miR-17-92 in pancreatic CSCs, where the expression of this cluster is 
significantly lower. For this purpose, we used a lentiviral construct (Lenti-miR) containing 
GFP and the common precursor of miR-17-92 (or scrambled control; Lenti-Ctrl) under the 
CMV promoter and an inducible system with doxicyclin containing mCHERRY. We first 
confirm up-regulation of miR-17-92 family members in PDAC spheres infected with Lenti-





                                              
Figure 19. Lentiviral overexpression of miR 17-92 in spheres derived cells: representative 
images of GFP expression in spheres derived cells post infection and sorting strategy (upper panel) 
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5.1. Cancer stem cell phenotype 
 
Using flow cytometry analyses we assess the expression of the CSC surface markers CD133 
and SSEA-1, and observed that both markers were significantly decreased in Lenti-miR cells 
(Figure 20A), suggesting a possible transition of CSCs to a more differentiated phenotype. 
Along these lines, we also observed reduction in the expression of pluripotency associated 
genes (Oct4, Sox2, Klf4 and Nanog) (Figure 20B) and diminished sphere formation capacity 
across primary cells derived from several tumours (Figure 20C) following overexpression of 
the miR-17-92 cluster.  
 
 
             
Figure 20. (A) QPCR analysis of pluripotency-associated genes (Oct4, Sox2, Klf4 and 
Nanog) in cells overexpressing miR-17-92 compared with the control. (B) Fold change in surface 
expression of CD133 and SSEA1 in cells overexpressing miR-17-92 compared with control. (C) 
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Moreover, cell cycle analysis revealed a decrease in cells residing in G0- and G1-phase and an 
increased fraction of cells in S-phase upon overexpression of miR-17-92 indicating a less 
quiescent phenotype (Figure 21A). Importantly, we did not observe alterations in the level of 
β-galactosidase staining indicating that there are no changes in terms of senescence (Figure 
21B). This hypothesis was functionally confirmed by PKH26 labeling of cells overexpressing 
miR17-92 that show a rather reduced quiescence compared with control cells (Figure 21C).  
 
 
These changes in terms of CSC content and cell cycle are translated into marked increase in 






Figure 21. (A) Cell cycle analysis using ki67 and Dapi (B) Representative images showing 
β-galactosidase staining in spheres derived cells overexpressing miR-17-92 compared with control. 
(C) Percentage of PKH26+ cells during 4 weeks in spheres derived cells overexpressing miR-17-92 
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5.2. In vitro and in vivo migration capacity 
 
Within the tumour exist a subpopulation of migrating cancer stem cells (CSCs) represents the 
exclusive source for metastasis in a model of pancreatic cancer (Hermann et al., 2007b, 
Hermann et al., 2008). Based on previous studies, Nodal/TGF-β1 signaling plays a pivotal 
role in the migration and invasion of pancreatic CSCs (Lonardo et al., 2011, Gaspar et al., 
2007, Teraoka et al., 2001), To further investigate the migrating and invasive capacity of the 
primary pancreatic cancer cells after overexpression of miR-17-92, we used several 
chemoattractant based on the previous studies linking them into a more CSC associated 
phenotype: TGF-β1 Nodal and Activin. Using wound healing assay to measure the migrating 
capacity, we observed that control cells responded robustly to TGF-β1 and Nodal, 
respectively, while cells over-expressing miR-17-92 had completely lost their responsiveness 
(Figure 23A). As expected the small molecule inhibitor of Alk4 and TGFBR2 reversed the 
capacity of control cells to migrate in the presence of TGF-β1 or Nodal, the effect was more 
pronounced in cells over-expressing miR-17-92, indicating an impairment of the 
Nodal/TGF-β1 pathway even prior to treatment with SB431502. To confirm our results in a 
                                       
Figure 22. Chemoresistance by Annexin V/Dapi staining after 7 days treatment with 
Gemcitabine. 
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different experimental setting, we used Boyden chamber invasion assays and observed that the 
invasion capacity of cells over-expressing the miR-17-92 cluster was also strongly reduced in 
the presence of Nodal, Activin and TGF-β1 (Figure 23B).  
 
 
To further validate these findings in vivo, we injected sphere-derived Lenti-Ctrl and 
Lenti-miR infected cells, respectively, into the spleen of NSG mice to assess liver 
dissemination and subsequent metastasis. Ten weeks post-injection, we observed reduced cell 
dissemination to the liver (i.e. micro-metastases) in mice injected with cells overexpressing 
miR-17-92, as determined by immunohistochemistry of the livers and qPCR for mCHERRY 
and hGAPDH (Figure 24A). Our findings were corroborated by ex vivo whole tissue 
immunohistochemistry demonstrating the presence of cells positive for human-specific ALU 






   
Figure 23. (A) Quantification of migration using wound-healing assay with stimulation of 
Nodal, TGF-ß1 and inhibition with SB 431502. (B) Representative images of invaded cells (upper 
panel). Percentage of invading cells through MatrigelTM following stimulation with Nodal, Activin 







C- FBS 20% Nodal Activin TGFb 
Control Mir 







































TGF-!1 odal Nodal 




– – – 
– 
Lenti-Ctrl Lenti-miR * 
* 
* 






























96	   	  	  
 
 
5.3. In vivo tumourigenicity  
 
Interestingly, despite the higher proliferation rate of cells transduced with miR-17-92, these 
cells produced significantly fewer tumours in a dose-dependent manner compared to cells 
transduced with a miR-Control construct (Figure 25A). Based on our in vitro results 
demonstrating that miR-17-92 expression reverses CSC quiescence, we next asked whether 
miR-17-92 overexpression specifically affects the long-term repopulation capacity of CSCs as 
assessed by serial transplantation of the tumours. During the first in vivo passage, we observed 
a higher proliferation rate for miR-17-92 overexpressing cells compared to the control 
tumours (Figure 25B), which closely mimicked the proliferation pattern of these cells in vitro. 
In contrast, however, during the subsequent two in vivo passages, miR-17-92 overexpressing 
cells gradually lost their potential to expand and eventually exhausted.  
 
Figure 24. (A) QPCR quantification of mCHERRY copies for µg of total RNA extracted 
from fresh livers after intra-splenic injection of 5*104 cells overexpressing miR-17-92 and control 
into NSG mice. (B) Representative immunohistochemistry images of pancreatic cancer cell 
human micrometastasis in mouse livers 10 weeks after intrasplenic injection. Arrows indicate cells 
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These results were further corroborated by sphere formation assays using cells harvested at the 
end of each of the three in vivo passages. Consistently, we found that the self-renewal 
capacity of miR-17-92 overexpressing cells had decreased over time in vivo (Figure 26A). 
Cell cycle analysis validated the initial increase in proliferation, which eventually culminated 
in their exhaustion (Figure 26B). Since cell-cycle restriction has been suggested as a 
mechanism to limit DNA damage and subsequent stem cell loss (Viale et al., 2009), we next 
assessed the level of DNA damage. For this purpose, the extend of phosphorylated histone 
H2A variant H2AX (δH2AX), which forms foci at sites of DNA double-strand breaks, was 
determined by confocal microscopy. In line with our cell cycle and in vivo exhaustion data, we 
found that cells over-expressing miR-17-92 showed more frequently gH2AX foci as 
compared to Lenti-Ctrl cells; a difference that further increased upon treatment with 








Figure 25. (A) In vivo tumorigenicity of cells overexpressing miR-17-92 compared with 
control cells and (B) in vivo serial transplantation.	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Together, these results suggest that over-expression of miR-17-92 in CSCs results in loss of 
cell-cycle restriction/checkpoints by downregulation of p21 leading to an accumulation of 
DNA damage and eventually this mitotic chaos translates into CSCs exhaustion (Viale et al., 














Figure 26. (A) Numbers of spheres during in vivo passages. (B) Cell cycle analysis using 
ki67 and Dapi of freshly isolated cells after in vivo serial transplantation. (C) Quantification of 
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6. MIR-17-92 TARGETS NODAL/TGFβ SIGNALING 
 
The miRNAs exert their regulatory effects by binding to complementary sites within the 3' 
untranslated regions (UTRs) of their mRNA targets. The formation of the double-strand 
RNA, resulting from the binding of the miRNA, leads to translational repression (Bartel, 
2004). We took advantages of one of the available miRNA targets databases, TargetScan 
(http://www.targetscan.org), to search for potential targets of miR-17-92. We identified 
conserved binding sites for several members of miR-17-92 cluster in the 3’-UTR region of 
the Activin-like 4 (ALK4), TGF-β Receptor-2 (TGFBR2), SMAD2, and SMAD4 genes, a 
core group of regulatory genes known to govern the stemness and/or metastasis of pancreatic 
CSCs (Lonardo et al., 2011), p21 and p57, main regulators of quiescence (Matsumoto et al., 
2011, Kippin et al., 2005, Cheng et al., 2000) and TBX3, which has been implicated in the 
regulation of self-renewal of embryonic stem cells (Lu et al., 2011) and CSCs (Fillmore et al., 
2010) (Figure 27A and Figure 27B).  
                   
Figure 27. (A) Grafic representation of predicted targets of miR-17-92 cluster. (B) 
Sequence alignment of miR-17-92 family seed sequence in TGFBR2 3′ UTR, ALK4 3′ UTR, 
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To validate these genes as direct functional targets of miR-17-92 in primary PDAC cultures, 
we analysed a panel of primary pancreatic cancer cells expressing doxycycline-inducible Lenti-
miR-17-92 or miR-control. After 96h treatment with doxycycline, we performed flow 
cytometry analysis for ALK4 cell surface expression and we observed a decrease in several 
primary pancreatic cancer cells upon overexpression of miR-17-92 (Figure 28A). Moreover, 
western blot analysis for p21, p57, pSMAD2 and Tbx3 shows a marked reduction of the 
protein levels after stimulation with doxycyclin and increase expression of miR-17-92 (Figure 
28B).  
 
We further validated the predicted targets analyzing the RNA expression by qPCR; for all 
target genes, we observed a marked reduction in their expression in CSCs over-expressing 
miR-17-92. (Figure 29A). We also validate the regulation of the predicted targets by single 
members of miR-17-92 cluster by qPCR using antagomirs, which reflect the predictions 
obtained for single family members using Targetscan (Figure 29B). 
 




Figure 28. (A) Flow cytometry analysis for ALK4 before and after treatment with 
Doxicyclin 96h. (B) Western blot analysis of cell cycle gene p21, p57, pSMAD2 and TBX3. 
Normalization using GAPDH 	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To examine whether miR-17-92 members were able to interact with the 3′ UTR of Alk4 and 
Tbx3, we conducted a luciferase reporter assays. The complete 3′ UTR of Alk4 or Tbx3 gene 
was cloned into the GLuc Dual-luciferase reporter vector. The cells were co-transfected with 
GLuc vector containing the 3′ UTR of Alk4 or Tbx3 and miR-17-92 mimics: the results 
showed significantly lower expression of the luciferase compared with the cells transfected 
with the same reporter vector and control microRNA mimics (NC) (Figure 30). 
 
Figure 29. (A) QPCR analysis of miR-17-92 target genes after 72h treatment with 
Doxicyclin. Data are normalized for ß-Actin expression. (B) QPCR analysis of miR-17-92 target 
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Figure 30. The complete 3′ UTR of Alk4 and Tbx3 genes were cloned into the GLuc 
Dual-luciferase reporter vector and co-transfected with miR-17-92 mimics and control miR 
mimics, respectively. The Gaussia luciferase activity was measured and normalized to Renilla 
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To functionally validate SMAD4 as direct target of miR-17-92, we used a pCAGA12-
luciferase SMAD4 reporter in primary spheres derived cells overexpressing miR-17-92. After 
stimulation with Tgf-β1, Nodal and Activin we were able to observe an increase in the 
luciferase signal in control cells, while the effect is significantly reduced in cells overexpressing 
miR-17-92 meaning that SMAD4 is strongly inhibited by miR-17-92 (Figure 31A). 
Subsequently, we used the same cells stimulated with Tgf-β1, Nodal and Activin to evaluate 
the ability to induce the expression of p21, Tbx3 and pSMAD2. In control cells we observed 
an increase of p21, Tbx3 and pSMAD2 both at RNA and protein level, while in cells 






Figure 31. (A) Luciferase activity of pCAGA12-luc SMAD4 reporter after stimulation 
with Tgf-β1, Nodal and Activin in cell overexpressing miR-17-92 versus control cells. (B) QPCR 
for p21 and Tbx3 (upper panel) and western blot analysis for pSMAD2, p21 and GAPDH (lower 
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7. IDENTIFICATION OF MASTER REGULATORS OF SELF-
RENEWAL AND CHEMORESISTANCE OF PANCREATIC 
CANCER STEM CELLS 
In order to functionally validate the importance of miR-17-92 target genes in the 
regulation of CSC self-renewal and chemoresistance, we decided to perform knockdown 
experiments using shRNAs against target protein identified previously. Has been already 
shown, in a previous work, that genetic targeting using shRNA against Alk4, Nodal and 
SMAD4 reduced sphere formation capacity and CD133 expression and abrogates in vivo 
tumourigenicity of primary pancreatic cancer cells (Lonardo et al., 2011). We decided to 
knockdown p21 and Tbx3 in pancreatic cancer stem cells to determine the involvement in 
self-renewal capacity, invasion and chemoresistance.  
 
7.1. p21 regulates quiescence and chemoresistance 
 
Emerging evidences suggest that p21 plays a pivotal role in maintaining stem cell quiescence 
where its absence induces a rapid exhaustion of haematopoietic stem cells (HSCs) (Cheng et 
al., 2000). More importantly p21-induced cell cycle arrest is required for self-renewal because 
prevent the accumulation of excessive DNA damage and functional exhaustion of rapidly 
dividing leukaemia cells (Viale et al., 2009) and colon cancer stem cells (O'Brien et al., 2012). 
We asked whether p21 could possess the same properties in the contest of pancreatic cancer 
stem cells. Analysis of spheres derived cells enriched for chemoresistant CSCs shows a 
marked increase of p21 at protein and RNA levels compared with the more differentiated a 
proliferative adherent cells (Figure 2 and Figure 3). We used a short-hairpin RNA (shRNA) 
targeting p21 (sh-p21) to specifically suppress the expression of p21 in a panel of primary 
pancreatic spheres derived cells with a different degree of inhibition assessed by densitometric 
quantification (Figure 32A). Knockdown of p21 also inhibited sphere formation capacity 
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Cell cycle analysis of shp21 cells show increased in the overall proliferation of the cells, as 
determined by cell cycle analysis (Figure 33A). Moreover, p21 knockdown resulted in a more 
chemosensitive phenotype after treatment with Gemcitabine (Figure 33B). Therefore, we 
were able to recapitulate some of the phenotypes observed in the miR-19-72 over-expression 
studies by merely silencing p21 as one of the many targets of the miR-19-72 cluster. 
 
 
Figure 32. (A) Western blot analysis of p21 in cells infected with lentivirus shp21 
compared with scramble (upper panel) and densitometric quantification of protein bands (lower 
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Figure 33. (A) Cell cycle analysis using Ki67 by flow cytometry. (B) Chemoresistance by 
Annexin V/Dapi staining after treatment with Gemcitabine in shp21 cells compared with 
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Therefore, p21 appears to have a dominant role in CSCs and targeting p21 may have 
important anti-CSCs consequences. Thus, to validate our findings in vivo, we injected 
limiting dilutions of sh-scramble and sh-p21 cells into immunocompromised mice to assess 
the tumourigenic capacity of pancreatic CSCs lacking p21. Intriguingly, in vivo 
tumourigenicity was significantly impaired, particularly when low numbers of cells were 
injected (Figure 34).  
 
 
This result is consistent with the effect of miR-17-92 over-expression, which further supports 
that the suppression of p21 might be the key player by which the miR-17-92 cluster regulates 
self-renewal and chemoresistance of pancreatic CSCs together with the abrogation of the 
Nodal/ TGF-β1 pathways. 
 
7.2. Tbx3 regulates self-renewal capacity and metastasis 
 
TBX3 is a transcription factor that belongs to the T-box gene family and contain a conserved 
DNA-binding domain called the T-box (Bamshad et al., 1997). TBX3 plays an essential role 
in embryogenesis and stem cells (Pirity and Dinnyes, 2010) and very recently has been also 
found overexpressed in several cancers, including breast, pancreatic, liver, bladder, and 
melanoma, and there is strong evidence linking it to the oncogenic process (Renard et al., 
2007, Fan et al., 2004, Peres and Prince, 2013). In order to evaluate if TBX3 is important for 
pancreatic cancer stem cells, we analyzed spheres derived cells and we observed that TBX3 is 
         
Figure 34. In vivo tumorigenicity with limiting dilution of sh-p21 cells compared with 
scramble cells 
1x104 1x103 1x102 
Scramble 
sh-p21 
Tumor take after two months 
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upregulated both at protein (Figure 35A) and at RNA level (Figure 35B) compared with 
adherent cells. 
Moreover, we corroborated our results in a different set of CSC comparing the expression of 
TBX3 in CD133 sorted cells (Figure 36A) and in ALK4 sorted cells (Figure 36B). TBX3 
resulted upregulated in both CSC enriched populations. 
 
 
Figure 35. (A) Western blot analysis of TBX3 comparing adherent and spheres from 
several primary pancreatic cancer cells (upper panel) and densitometric quantification of the 
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Figure 36. (A) Western blot analysis of TBX3 in CD133 positive and negative cells 
(upper panel) and densitometric quantification of the western blot (lower panel). (B) QPCR 
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Next we asked whether specific knockdown of TBX3 could affect the cancer stem cells 
population, inhibiting the mechanisms of self-renewal, metastasis and tumourigenicity. Using 
a lentiviral vector expressing two different shRNA against TBX3, we obtained stable spheres 
derived cells with TBX3 knockdown (Figure 37A). Flow cytometry analysis of sh-TBX3 cells, 
shows a significant reduction of CSC surface markers CD133 and CXCR4 compared with 
scramble cells (Figure 37B). 
 
Very recently TBX3 has been identified as TGF-β1 target with a double function: inhibition 
of proliferation and promotion of the migration of breast epithelial cells (Li et al., 2013). 
Based on these findings, we decided to test migration and invasion capacity of knockdown 








            
Figure 37. (A) Western blot analysis of TBX3 in cells infected with lentivirus expressing 
sh1 and sh2 (upper panel) and densitometric quantification of the western blot (lower panel). (B) 
Flow cytometry analysis for CSC surface markers CD133 and CXCR4 in cells expressing sh-
TBX3 compared with scramble. 
Tbx3 
GAPDH 
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8. TARGETING QUIESCENT CSCS AS A NOVEL THERAPEUTIC 
APPROACH FOR PANCREATIC CANCER  
Since the sum of our data show that the miR-17-92 cluster possesses strong inhibitory 
effects on CSC phenotypes by targeting key factors essential for the stem-like nature of 
CSCs, we finally aimed to test the translational relevance of our findings. Thus, we performed 
in vivo therapeutic intervention studies by inducing over-expression of miR-17-92 in 
established pancreatic tumors using a doxycycline-switchable system. First, we implanted 
transduced, but doxycycline naïve cells into immunocompromised mice and once tumors had 
formed (~100mm3), doxycycline was administered to induce miR-17-92 expression. In 
addition, some mice were also treated with Gemcitabine (biweekly 125 mg/kg i.p.) from day 
14 to 64, to mimic standard of care. Intriguingly, while no significant differences were 
observed between Lenti-control tumors and Lenti-miR tumors with respect to bulk tumor 
growth when the 17-92 cluster was expressed post tumor formation, tumors over-expressing 
the miR-17-92 cluster were significantly more sensitive to Gemcitabine compared to control 
tumors (Figure 38A). In addition, analysis of tumor weight showed a significant reduction for 
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Importantly, flow cytometry analysis after digestion of the tumours, shows a significant 
decrease in CSC markers CD133, CXCR4 and SSEA1 in tumours overexpressing miR-17-
92 and treated with gemcitabine (Figure 39A). Moreover, injection of isolated cells from the 
tumours in a serial dilution manner further enhanced this difference, showing reducing 
tumourigenicity of cells overexpressing miR-17-92 and treated with gemcitabine meaning 
that high levels of miR17-92 forced the cells in a more differentiated and proliferative state 
that sensitized them to chemotherapy, reducing their self-renewal capacity in vivo and at the 




Figure 38. (A) Experimental setup for in vivo treatment (upper panel) and treatment 
effects of gemcitabine in miR-17-92 overexpressing cells in established tumors derived from 185 
cells in immunocompromised mice (lower panel). The mean tumor volume is given; n 6 tumors 
per group. P value was determined by Student t test. (B) Representative picture (upper panel) and 
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Figure 39. (A) Flow cytometry analysis for CSC markers CD133, CXCR4 and SSEA1 in 
cells isolated from the tumors (B) In vivo tumorigenicity of cells isolated from the tumors in a 
serial dilution assay. 
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Patients with pancreatic ductal adenocarcinoma are still suffering from a devastating 
prognosis due to lack of early symptoms, reliable methods for detection and early metastatic 
spread. Current available treatments are not very effective due to intrinsic chemoresistance 
and only small advances have been achieved in terms of new therapeutic approaches, while 
still eventually most of the patients succumb from disease resulting in a dismal 5-year survival 
rate of below 5%. Recent studies on pancreatic cancer identified a subpopulation named 
cancer stem cells (CSCs), which possess exclusive tumourigenicity based on their unlimited 
self-renew capacity and recapitulate the cellular heterogeneity of the parental tumour. Of 
Clinical utmost importance is their strong resistance to conventional chemotherapeutics 
compared to their differentiated progenies resulting in tumour recurrence following initial 
tumour regression in response to anticancer chemotherapy. Therefore, elimination of the 
more differentiated cancer cells, even if associated with significant tumour size reduction, is 
unlikely to lead to the eradication of the tumourigenic potential of the tumour, as this is 
restricted to the CSC population. These findings have opened a new research field focussing 
on a better understanding of CSC biology and have spurred renewed hope for the 
development of novel and more effective CSC-specific targeted therapies in combination with 
effective treatments against bulk tumour cells. To achieve the latter, it is essential to elucidate 
the signalling and regulatory mechanisms that are unique to CSCs.  
Previous studies, including our own have shown that pancreatic cancers contain a rare 
population of undifferentiated cells that are characterized by expression of CD133 or 
CD44/CD24 (Li et al., 2007b, Hermann et al., 2007b). Moreover, it has also been shown, 
that it is possible to enrich and expand pancreatic CSCs in vitro as anchorage-independent 
spherical colonies termed spheres. These spheres are composed of a subset of cells with stem 
cell-like properties including the ability to form secondary spheres as well as more 
differentiated progenies. Molecular and biological characterization of pancreatic CSCs using 
these in vitro as well in vivo approaches indicates that several pathways are indispensable for 
the maintenance of their self-renewal capacity and subsequently also for their exclusive  in 
vivo tumourigenicity. Specifically, the Nodal/Activin pathway is essential for the regulation of 
stemness properties of pancreatic CSCs. The ligands are expressed in pancreatic CSCs 
regulating self-renewal and metastasis, but also in activated pancreatic stellate cells (PSCs), 
which are abundantly present in the stroma surrounding pancreatic cancer cells and serve as a 
CSC niche (Lonardo et al., 2011, Lonardo et al., 2012).  Building on these original findings, 
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in the first part of this Doctoral Thesis, we aimed to better characterize pancreatic CSCs 
using different approaches in order to discover new regulatory pathways with particular 
emphasis on self-renewal and chemoresistance, respectively.  
For this purpose, we first analysed sphere-derived cells enriched for cancer stem cells and 
found that besides the over expression of surface CSCs markers (CD133, CXCR4 and 
SSEA1) and pluripotency associated genes (Oct4, Sox2, Klf4 and Nanog), they also possess a 
specific cell cycle signature with an increase both at RNA and protein level of p21, p27 and 
p57 that are involved in the maintenance of a quiescent or slow proliferating phenotype. 
Further experiments using cell cycle analysis and the label-retaining technique, which is based 
on the retention of the lipophilic dye PKH26 conclusively demonstrated the presence of a 
slow proliferating population bearing all the characteristics of CSCs. 
Secondly, we focussed our attention on chemoresistant CSCs both in vivo and in vitro: we 
found that gemcitabine leads to a relative increase in the number of CSCs as evidenced by 
increased expression of CSC surface markers and enrichment of a cancer stem cell-like gene 
signature, indicating a preferential targeting of more differentiated cells. Moreover, cell cycle 
analysis showed that rapidly proliferating cancer cells were quite efficiently eliminated by 
treatment with gemcitabine, while more quiescent cells survived; an observation that is in line 
with previous findings (Scopelliti et al., 2009). 
Self-renewal and chemoresistance are both highly orchestrated processes that require complex 
transcription and posttranscriptional regulation of gene expression. miRNAs target multiple 
genes and play important roles in many cancer processes. In an effort to discover targetable 
signalling pathways present in drug-resistant CSCs, we next examined miRNA expression 
signatures enriched by chemotherapy in primary pancreatic cancers cells. RNA extracted from 
sphere-derived cells and gemcitabine-resistant tumours and cells, respectively showed a 
specific and common miRNA expression profile across several tumours tested.  
Specifically, we found that the miR-17-92 cluster, composed by six members miR-17, -18a, 
19a, 19b, 20a and -92a, is markedly suppressed in sphere-derived cells and chemoresistant 
pancreatic CSCs as compared to their more differentiated counterparts. These findings are 
intriguing as the cluster is regularly overexpressed in cancer (reference) and the oncogenic 
nature of miR-17-92 activation is well established (He et al., 2005, O'Donnell et al., 2005), 
Loss of heterozygosity at 13q12-q13 is associated with multiple tumour progression and poor 
prognosis, including breast cancer, squamous cell carcinoma of the larynx, retinoblastoma, 
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hepatocellular carcinoma and nasopharyngeal carcinoma (Xiang and Wu, 2010, Coller et al., 
2007) and deletion of miR-17-92 cluster was observed in a relevant percentage of ovarian 
cancers, breast cancers and melanomas (Zhang et al., 2006). However, the miR-17-92 cluster 
has also been demonstrated to act as a tumour suppressor in breast cancer cells (Hossain et al., 
2006), in gastrointestinal stromal tumours (Gits et al., 2013) and in oral squamous carcinoma 
(Chang et al., 2013). These observations may reflect the functional complexity of mir-17-92 
rendering the biological response dependent on tumour type and cell type. 
Even more importantly, the underlying targets and signalling cascades that are deregulated in 
response to modulation of miR-17-92 still remain largely elusive as of today. Strikingly, 
studies that mostly aimed at determining miR-17-92 targets have focused on individual 
members of the cluster, despite the observation that the entire cluster is regularly activated in 
cancer (references). Specifically, different members?? of the cluster have recently been shown 
to target diverse pathways, including TGF-β1 (Dews et al., 2010) and HIF-1α signalling 
(Taguchi et al., 2008), but their role in the regulation of pancreatic cancer and pancreatic 
cancer stem cells in particular remained to be determined.  
Our data now demonstrate in a large set of primary cells and (fresh) primary patient tissues, 
that inhibition of miR-17-92 by means of specific antagomirs in more differentiated cells 
equipped them with CSCs features that are regularly restricted to bonafide CSCs. This was 
evidenced by up-regulation of CD133, increased sphere formation capacity, reduced 
proliferation with subsequent increase in chemoresistance. Most importantly, antagomirs 17-
92 significantly promoted their in vivo tumourigenicity and in vivo resistance to 
chemotherapy.  
On the contrary, in gain-of-function experiments using a lentiviral approach, we 
overexpressed miR-17-92 in sphere-derived cells in order to push the cells in a more 
differentiate state. Indeed, we observed a significant decrease in sphere formation capacity, a 
reduction of CSCs surface marker expression and increased proliferation. The latter finding 
was most intriguing as it resulted in subsequent exhaustion of the slow cycling cells, wich was 
reflected in increased sensitivity for treatment with gemcitabine. Moreover, it has previously 
been demonstrated that acquisition of an invasive phenotype represents a critical initiation 
step in the process of pancreatic cancer cell dissemination (Rhim et al., 2012) and that a 
subset of CSCs possess particular metastatic capabilities (Hermann et al., 2007b). Therefore, 
we next tested migration and invasive capacity of sphere-derived cells in the presence or 
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absence of miR-17-92 following stimulation with Nodal, Activin and TGF-β1, which we 
have demonstrated as main drivers of the metastatic phenotype in pancreatic cancer (Lonardo 
et al., 2011). Overexpression of miR-17-92 family members significantly reduced migration 
and invasion capacity in vitro, and more importantly we also demonstrate the complete 
inhibition of liver metastasis in vivo after intrasplenic injection of sphere-derived cells 
overexpressing miR-17-92. Subsequent in vivo experiments showed a reduction of 
tumourigenicity in dose dependent manner and exhaustion of the CSCs pool during serial in 
vivo passaging, which most likely is related to the extensive proliferation of the cells 
overexpressing miR-17-92 and subsequent accumulation of DNA damage due to alteration of 
mechanism of DNA damage repair (see below).  
While the aforementioned studies establish the miR-17-92 cluster as a key negative regulator 
of pancreatic CSCs function. Next step was to identify specific targets that could be linked to 
the strong phenotype observed in response to modulation of miR-17-92 cluster expression. 
For this purpose, we used Targetscan software to define putative single miRNA targets. 
Intriguingly, we were able to identify several targets clustering around pathways that 
previously have been associated with the regulation of CSCs; e.g. Nodal/Activin pathway and 
cell cycle regulators. Specifically, we found miR-18a to regulate both SMAD2 and SMAD4, 
two key components of the Nodal/Activin signalling cascade, suggesting that miR-18a 
substantially contributes to deregulation of this CSC pathway by regulating a selected set of 
target genes. Moreover, miR-17 and miR-20a showed a more wide range of targets since they 
are able to inhibits TGFBR2, ALK4, SMAD4, as well p21 and TBX3, all of which are again 
linked to Nodal/Activin signalling and cell cycle regulation, respectively. Finally, miR-92a 
was shown to also target TBX3, but also p57. Therefore, our data demonstrate that miR-17-
92 dampens Nodal/Activin signalling in a multifaceted way by acting both upstream and 
downstream of pSMAD2/SMAD4, further underscoring its ability to regulate multiple 
components of the same CSC pathway. The ability to simultaneously target different 
components of the signalling cascade, as well as the downstream effectors through multiple 
miRNAs belonging to the same cluster, allows for a very tight control of the Nodal/Activin 
transcriptional programme. Moreover, it renders the cells with strong plasticity for the 
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We observed that p21 was highly expressed in sphere-derived cells as well as chemoresistant 
cells compared to their respective counterparts. This result suggests that in the context of 
CSC biology, p21 may serve to maintain tumour-initiating potential by keeping their 
proliferative activity in check. Indeed, there is strong evidence from murine models of normal 
hematopoietic and leukemic stem cells that p21 is an important regulator of self-renewal. In 
the absence of p21, both normal hematopoietic stem cellas as well as transformed leukemic 
stem cells underwent functional exhaustion and were unable to maintain the clone (Cheng et 
al., 2000, Viale et al., 2009). Our data now also support a role for p21 in the prevention of 
pancreatic CSCs exhaustion through cell-cycle restriction, which resulted in the accumulation 
of DNA damage as evidenced by increased gH2AX foci and may result in the 
elimination/dysfunction of the cells via mitotic chaos. These results are consistent with a 
number of publications that have recognized a role for p21 in the protection of cancer cells 
from stress and DNA damage (Gorospe et al., 1996, Tian et al., 2000, Bene and Chambers, 
2009). Importantly, we validated these results using an shRNA approach and observed that 
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p21 knockdown consistently affected the self-renewal capacity as well chemoresistance of 
pancreatic CSCs. Finally, we also show that the Nodal/Activin/TGFb-mediated increase in 
p21 expression is Smad2 dependent manner.  
Considering the widespread expression of Alk4 in CSCs and the functional involvement of 
Alk4 in mediating CSC self-renewal and invasiveness, the suppression of Alk4 by miR-17-92 
reveals a previously unknown epigenetic regulation in pancreatic CSCs. Even more important 
from a clinical point of view, abrogation of Nodal/Activin signalling via miR-17-92 
overexpression could be a promising and highly specific therapeutic approach, as it would not 
only result in reduced expression of Alk4, but also induce direct miR-17-92-mediated 
repression of Nodal/Activin responsive genes. The latter would avoid the bias of the SMAD4 
status as Smad4 is mutated in about 50% of pancreatic tumours (Schneider and Schmid, 
2003) and therefore a significant proportion of tumours may not be responding to 
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We provide compelling functional evidence for downregulation of miR-17-92 in 
preferentially quiescence and chemoresistance in pancreatic CSCs. In summary we found: 
1. Spheres-derived cells are enriched for CSCs as evidenced by enhanced expression of 
surface markers CD133, CXCR4 and SSEA1, pluripotency-associated genes (Oct4, 
Sox2, Klf4, Nanog), a slow cycling phenotype with increased expression of p21, p27 
and p57 and increased chemoresistance; 
2. Treatment with Gemcitabine enriched for CSCs with above stem-like gene signature 
and slow proliferation profile both in vivo and in vitro; 
3. Sphere-derived cells and chemoresitant cells show a consistent and specific miRNA 
expression profile with a significant downregulation of miR-17-92 family; 
4. Inhibition of miR-17-92 by antagomirs in differentiated cancer cells induced a CSCs 
phenotype accompanied by increased expression of CD133, enhanced sphere 
formation capacity, reduced proliferation and increased chemoresistance; 
5. Lentiviral overexpression of miR-17-92 in CSCs reverted the CSCs phenotype as 
evidenced by reduced surface expression of CD133 and CXCR4, deminished sphere 
formation capacity, impaired invasiveness in vivo and in vitro, reduced tumourigenicity 
and eventually exhaustion during serial in vivo passaging; 
6. We identified several target genes that belong to the Nodal/Activin/TGFb signalling 
pathways (ALK4, SMAD4, SMAD2) as well as regulators of the cell cycle (p21 and 
p57) and self-renewal and metastasis (TBX3); 
7. shRNA-mediated knock down of p21 diminished self-renewal capacity, cell cycle 
progression and chemoresistance as well in vivo tumorigenicity; 
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Con esta tesis demostramos grandes evidencias funcionales  donde se observa que la expresión 
de miR-17-92 está inhibida de manera más frecuente en células quiescentes y 
quimioresistentes de las CSCs pancreáticas. En resumen, hemos demostrado: 
1. Las células obtenidas de esferas están enriquecidas en CSCs, ya que la expresión de los 
marcadores CD133, CXCR4 y SSEA1 es mayor, como también los genes asociados a 
pluripotencia (Oct4, Sox2, Klf4, Nanog).Además también se evidencia un fenotipo 
con ciclo celular lento, con aumento de la expresión de p21 y p57, asi como también 
un aumento de la quimioresistencia; 
2. El tratamiento con la Gemcitabina enriquece en CSCs debido a que aumentan la 
expresión de los genes asociados a pluripotencia y decrece el patrón de proliferación 
tanto in vivo como in vitro; 
3. Las células derivadas de esferas y las células quimioresistentes muestran un perfil de 
expresión de miRNA específico y consistente  con una inhibición de la expresión de la 
familia de miR-17-92; 
4. La inhibición de miR-17-92 con antagomirs en células cancerígenas diferenciadas 
induce un fenotipo asociado a célula troncal cancerígina acompañado con aumento de 
la expresión del marcador CD133, mayor capacidad de formar esferas, reducción de la 
proliferación y aumento de quimioresistencia; 
5. La sobreexpressión de miR-17-92 mediante un lentivirus en las CSCs  reverte el 
fenotipo de CSC debido a que se evidencia una reducción de la expresión de los 
marcadores CD133 y CXCR4, baja la capacidad de formación de esferas, disminuye la 
capacidad de invasion in vivo e in vitro, se reduce la tumorigenicidad y eventualmente 
ocurre un reducción de formación de tumores en pases seriados a lo largo del tiempo; 
6. Hemos identificado distintos genes que pertenecen a las vías de señalización de 
Nodal/Activin/TGFb (ALK4, SMAD4, SMAD2), asi como reguladores del ciclo 
celular (p21 y p57) y también los implicados en la capacidad de auto-replicación y 
metástasis (TBX3); 
7. Los shRNA que median la inhibición de p21 bajan la capacidad de auto-replicación, la 
progresión celular y la quimioresistencia, asi como la tumorigénesis in vivo; 
8. Los shRNA que median la inhibición de TBX3 afectan la capacidad invasiae y de 
auto-replicación de las CSCs. 
CONCLUSIONES	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